

PROGRAMME

Joint Annual Meeting

German Society of Infectious Diseases (DGI)
German Center for Infection Research (DZIF)


Drug resistance in infectious diseases

28 – 30 September 2017

Hotel Empire Riverside Hamburg

10 Jahre Janssen HIV-Kompetenz

Gestern. Heute. Morgen.



- Weltweit über **330.000 behandelte Patienten**
- **Patienten-Portal**
MyMicroMacro.net
- **Aktuelle unterstützte Studien**, u. a. DUALIS, PROPHET, LOWER
- **Spotlight Fortbildungen**
- **Forschungsprojekte**
u. a. HIV-Impf-Programm



TABLE OF CONTENTS

Greeting / Grußwort	p. 4
Conference Chairs / Organizing Committee	p. 5
Programme at a Glance	p. 6
Scientific Programme	
Thursday, 28 September 2017	p. 8
Friday, 29 September 2017	p. 13
Saturday, 30 September 2017	p. 17
Poster Sessions / Poster Awards / DZIF TI-Forum.....	p. 20
Poster.....	p. 22
Speakers, Chairs, Experts and Presenting Authors	p. 44
Awards and Grants	p. 48
Exhibition Plan	p. 49
General Information	p. 50
Registration	p. 51
Exhibitors and Sponsors	p. 52
Travel Information.....	p. 55

Imprint

Responsible for editorial content

German Society of Infectious Diseases e.V. (DGI)
Nürnberger Straße 16 · 10789 Berlin

German Center for Infection Research e.V. (DZIF)
Inhoffenstr. 7 · 38124 Braunschweig


Design and Layout



COCSMEDIA

COCS media GmbH
Rosenheimer Str. 145c · 81671 Munich
www.cocs-media.de

COCS media GmbH does not guarantee the correctness of information.



Dear colleagues,

in the past few years, major progress has been made in the development of Infectious Diseases as a scientific and clinical specialty in Germany. The joint efforts of DZIF and DGI have led to significant achievements in basic science, clinical research and education.

The manifestations of Infectious Diseases and the associated challenges in Germany are constantly changing. International challenges such as epidemics that flare up quickly (e.g. Ebola), emerging infections (e.g. MERS, Zika), and questions relating to migrating populations have to be addressed. At the same time, the global spread of antibiotic resistance fuels the increase in drug resistance in German hospitals too.

We cordially invite you to the Joint Annual Meeting of the DGI and DZIF in Hamburg. We have put together a programme that links science and patient care and thus will provide a superb overview of the specialty of Infectious Diseases in Germany.

With the "Akademie für Infektionsmedizin" and the „Junge DGI“, we specifically want to attract young colleagues to the conference and to this exciting field. Antimicrobial drug resistance will thus be a focus of the meeting and is the topic of the plenary lecture and the panel discussion.

We look forward to welcoming you in Hamburg from 28 to 30 September 2017!

Sehr geehrte Damen und Herren,

in den letzten Jahren wurden große Anstrengungen unternommen, das Fachgebiet der Infektiologie in Deutschland weiter zu entwickeln. In Forschung, Klinik und Ausbildung konnte viel erreicht werden. Die DGI und das DZIF haben hierzu wichtige Beiträge geleistet.

Das Erscheinungsbild erregender Erkrankungen und die Herausforderungen für die Infektiologie in Deutschland wandeln sich ständig. Internationale Probleme wie rasch aufkommende Epidemien (Ebola), neue Viren (MERS, Zika) und Fragen der Flüchtlingsmedizin müssen angegangen werden. Gleichzeitig nehmen Antibiotika-Resistenzen weltweit und in deutschen Kliniken weiter zu.

Vor diesem Hintergrund laden wir Sie sehr herzlich zur gemeinsamen Jahrestagung der DGI und des DZIF nach Hamburg ein. Wir haben gemeinsam ein Programm geplant, das Wissenschaft und Klinik miteinander verknüpft und so einen sehr guten, aktuellen Eindruck der Infektiologie in Deutschland geben wird. Über die "Akademie für Infektionsmedizin" und die „Junge DGI“ wollen wir auch den Nachwuchs direkt ansprechen. Die Entwicklung von

Medikamentenresistenzen verschiedener Erreger wird bei der Tagung im Mittelpunkt stehen, was sich in der Auswahl des Plenarvortrags und der Podiumsdiskussion zeigt.

Wir freuen uns, Sie vom 28. – 30. September 2017 in Hamburg begrüßen zu dürfen!



Prof. Dr.
Rika Draenert



Prof. Dr.
Rolf Horstmann



Prof. Dr.
Ansgar Lohse



Prof. Dr.
Bernd Salzberger

Conference Chairs

DGI e.V.

Prof. Dr. Rika Draenert
University Hospital Munich

Prof. Dr. Bernd Salzberger
University Hospital Regensburg

DZIF e.V.

Prof. Dr. Rolf Horstmann
Bernhard Nocht Institute for
Tropical Medicine Hamburg

Prof. Dr. Ansgar W. Lohse
University Medical Center
Hamburg-Eppendorf

Organizing Committee

DGI e.V.


Prof. Dr. Gerd Fätkenheuer
Gisela Kremer
Charlotte Leisse




DZIF e.V.

Dr. Timo Jäger
Simone Friedrich
Tatiana Hilger












Thursday, 28 September 2017

09.00 - 10.30	MSD Symposium Superbugs: Panik oder Realität?  p.8
10.30 - 11.00	Coffee Break
11.00 - 11.10	Congress Opening p.8
11.10 - 12.40	Symposium I Global Spread of Resistance p.8
12.40 - 13.30	Lunch Break and Industrial Exhibition
13.30 - 14.30	Poster Session I p.9
14.30 - 15.00	DZIF Award Lecture p.9
15.00 - 16.30	Symposium II Novel Antiviral Treatment Strategies p.10
16.30 - 17.00	Coffee Break
17.00 - 18.30	Symposium III Immunotherapies and Vaccines p.11
from 18.30	Workshop Meet the Experts p.12

Friday, 29 September 2017

08.30 - 10.00	Symposium IV Microbiome and Infection p.13
10.00 - 10.30	Coffee Break
10.30 - 12.00	Symposium V Resistance in Nosocomial Infections p.14
12.00 - 13.00	Lunch Break and Industrial Exhibition Science Slam "Junge Infektiologen" p.15
13.00 - 14.00	Poster Session II
14.00 - 14.45	Infektiologie Quiz  p.15
14.45 - 15.15	Plenary Lecture p.16
15.15 - 15.45	Group Photo / Coffee Break
15.45 - 16.45	Podiumsdiskussion Bakterielle Resistenzen in Deutschland  p.16
16.45 - 17.15	Poster Awards and PhD Student Prizes  p.16
17.15 - 19.15	DGI General Assembly  p.16

Saturday, 30 September 2017


08.00 - 09.00	Akademie für Infektionsmedizin Reisemedizin  p.17
09.00 - 11.00	Symposium VI Drug Resistance and Control of Tuberculosis and Parasitic Infections p.17
11.00 - 11.30	Coffee Break
11.30 - 11.50	Preisvortrag Förderpreis für Klinische Infektionsforschung der DGI  p.18
11.50 - 13.10	Symposium VII Neues zum Thema X – aus der Infektiologie  p.18
13.10 - 13.20	Closing Remarks p.19

Rooms and Location

Scientific Programme: Ballroom (2nd level)


Coffee & Lunch Break / Industrial Exhibition: Foyer / Room 2A & 2B (2nd level)

Poster & e-Terminals: Room 3C+D (3rd level)




ST = Short Talk

9:00 – 10:30	MSD Symposium Superbugs: Panik oder Realität?
Ballroom	<i>Vorsitz: S. Hofer, Kaiserslautern</i>
9:00 – 9:30	Multiresistente gramnegative Erreger – Herausforderung für die Mikrobiologie? <i>R. Hoffmann, Augsburg</i>
9:30 – 10:00	Antibiotische Therapie resistenter gramnegativer Keime – neue Optionen für den Kliniker? <i>S. Hofer, Kaiserslautern</i>
10:00 – 10:30	Resistenzentwicklung und Antibiotika – ein Wettlauf mit der Forschung <i>T. Schneider, Bonn</i>
The Symposium is organized by MSD SHARP & DOHME GMBH, Munich.	
10:30 – 11:00	Coffee Break
11:00 – 11:10	Opening
Ballroom	<i>R. Draenert, Munich A. Lohse, Hamburg</i>
11:10 – 12:40	Symposium I: Global Spread of Resistance
Ballroom	<i>Chairs: M. Addo, Hamburg J. May, Hamburg</i>
11:10 – 11:30	DGI Lecture I
	Spread and evolution of broad spectrum β-lactamases <i>P. Nordmann, Fribourg/Switzerland</i>
11:30 – 11:40 ST 1	ESBL-producing Escherichia coli in Ghana – Is there transmission between poultry and humans? <i>D. Eibach, Hamburg</i>



11:40 – 11:50 ST 2	FungiScope™ – News on the Global Emerging Fungal Infection Registry <i>D. Seidel, Cologne</i>
11:50 – 12:10	DZIF Lecture I
	Toward Validating the Pathblocker Concept: Lead Generation and Optimization of PqsR Antagonists for the Treatment of Chronic Pseudomonas aeruginosa Infections <i>M. Empting, Saarbrücken</i>
12:10 – 12:20 ST 3	Trends bei übertragenen Resistenzen und zirkulierenden HIV-1 Subtypen - Ergebnisse der nationalen molekularen Surveillance in Deutschland 2013-2016 <i>A. Hauser, Berlin</i>
12:20 – 12:30 ST 4	A systematic analysis platform to elucidate the mechanism of action of novel antibiotics <i>A. Klöckner, Bonn</i>
12:30 – 12:40 ST 5	Hepatitis C Virus Screening Project of Patients on current anti- HCV Therapy <i>S. Sierra, Cologne</i>
12:40 – 13:30	Lunch Break and Industrial Exhibition
13:30 – 14:30	Poster Session I
	Room 3C+D (3 rd level)
14:30 – 15:00	DZIF Award Lecture
Ballroom	<i>Chair: M. Krönke, Cologne</i>



15:00 – 16:30 **Symposium II: Novel Antiviral Treatment Strategies**

Ballroom *Chairs: C. Lehmann, Cologne
T. von Hahn, Hanover*

15:00 – 15:20 **DGI Lecture II**

Therapy resistance under NAb in HIV infections
F. Klein, Cologne

15:20 – 15:30
ST 6 **The Hepatitis Delta International Network (HDIN) - Clinical and virological characteristics of patients with hepatitis delta infection and treatment approaches in different regions world-wide**
S. Hardtke, Hanover

15:30 – 15:40
ST 7 **A phase 2a, randomized study of romidepsin with or without 3BNC117 to evaluate the effects on the HIV-1 reservoir (ROADMAP)**
M. Platten, Cologne

15:40 – 16:00 **DZIF Lecture II**

Structure of Zika virus protease facilitates design of antivirals
R. Hilgenfeld, Lübeck

16:00 – 16:10
ST 8 **Labyrinthopeptins exert broad-spectrum antiviral activity through lipid-binding-mediated virolysis**
M. Brönstrup, Braunschweig

16:10 – 16:20
ST 9 **Wild birds - their underestimated role in the spreading of viral zoonotic pathogens**
U. Ziegler, Greifswald-Insel Riems

16:20 – 16:30
ST 10 **High-content screening identifies agonists for retinoic acid receptor as specific HBV/HDV inhibitors**
Y. Ni, Heidelberg

16:30 – 17:00 **Coffee Break**

17:00 – 18:30 **Symposium III: Immunotherapies and Vaccines**

Ballroom *Chairs: D. Busch, Munich
O. Witzke, Essen*

17:00 – 17:20 **DGI Lecture III**

Immunosuppressive agents and risk of infectious diseases
H. Guberina, Essen

17:20 – 17:30
ST 11 **Inhibition of IL-27R-mediated signaling results in strategic positioning of multifunctional T cells in granulomas of Mycobacterium tuberculosis-infected mice that is mediated by IL-17A**
C. Hölscher, Borstel

17:30 – 17:40
ST 12 **Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models**
E. Montoya-Diaz, Langen


17:40 – 18:00 **DZIF Lecture III**

NK cell-mediated recognition of HIV-1-infected cells – implication for immunotherapies
M. Altfeld, Hamburg

18:00 – 18:10
ST 13 **A donor-matched humanized mouse model reveals a chief role of the antigen-presenting cell-T cell interface on Ebola virus disease**
M. Rottstegge, Hamburg

18:10 – 18:20
ST 14 **MERS Vaccine development: Update on the Phase I First-in-human MVA-MERS-S trial**
T. Koch, Hamburg

18:20 – 18:30
ST 15 **Allogeneic Stem Cell Transplantation in HIV-1 infected Individuals The IciStem Consortium -The Role of Lymphocyte Populations**
J. Eberhard, Hamburg



ST = Short Talk

18:30 – 22:00 **Workshop „Meet the Experts“**

„MS Hanseatic“, Landungsbrücken

Empfang: 18:30


Abfahrt Rundfahrt: 19:30

Rückkehr: ca. 21:30

Themen: Neu auftretende Infektionen, HIV, Impfstrategien, NK Zellen in Virusinfektionen, Strategien zur Eindämmung Antibiotika-resistenter Erreger, Tropenkrankheiten, Medizinische Mikrobiologie 2030, Antibiotikaentwicklung, Tuberkulose

Experten: M. Addo, Hamburg; H.-J. Stellbrink, Hamburg; H. Streeck, Essen; M. Altfeld, Hamburg; L. Wieler, Berlin; G. Burchard, Hamburg; W. Solbach, Lübeck; R. Müller, Saarbrücken; S. Niemann, Borstel

Please find further information about the workshop at page 50.



© Joerg Modrow

8:30 – 10:00 **Symposium IV: Microbiome and Infection**

Ballroom *Chairs: I. Autenrieth, Tübingen
M. Vehreschild, Cologne*

8:30 – 8:50 **DGI Lecture IV**

Microbiome and complications of leukemia treatment and stem cell transplantation

E. Holler, Regensburg

8:50 – 9:00 **Metagenomic analysis of the effect of intestinal colonization with *Pseudomonas aeruginosa* on the mouse microbiome**

ST 16

F. Hölzl, Tübingen

9:00 – 9:10 **Distinct development of intestinal microbiota influenced by probiotics decreases risk of late onset sepsis in preterm infants**

ST 17

J. Pagel, Lübeck

9:10 – 9:30 **DZIF Lecture IV**

An approach to develop a novel strategy for treatment of antibiotic resistant bacterial pathogens

M. Schütz, Tübingen

9:30 – 9:40 **Lugdunin and beyond: Modulating human microbiomes to prevent endogenous opportunistic infections**

ST 18

A. Zipperer, Tübingen

9:40 – 9:50 **Alpha-diversity and the presence of the bile acid inducible operon (baiCD) in patients undergoing oral fecal microbiota transplantations (FMT) by capsule**

ST 19


F. Farowski, Cologne

9:50 – 10:00 **Enterohemorrhagic *Escherichia coli* (EHEC): A screening platform for factors influencing bacterial SOS-response and Shiga toxin expression**

ST 20

M. Koepfel, Munich

10:00 – 10:30 **Coffee Break**



10:30 – 12:00	Symposium V: Resistance in Nosocomial Infections
Ballroom	<i>Chairs: W. Kern, Freiburg H. Seifert, Cologne</i>
10:30 – 10:50	DGI Lecture V
	Diagnostic Stewardship <i>B. Sinha, Groningen/Netherlands</i>
10:50 – 11:00 ST 21	The value of the RNA helicase hslP as prognostic biomarker in patients with Pseudomonas aeruginosa bloodstream infection <i>M. Willmann, Tübingen</i>
11:00 – 11:10 ST 22	Carbapenem-resistant Gram-negative pathogens in a German University medical center: prevalence, clinical implications and the role of novel-lactam/-lactamase inhibitor combinations <i>F. Maurer, Hamburg</i>
11:10 – 11:30	DZIF Lecture V
	Perspectives on a One-Health approach from TTU HAARBI <i>E. Tacconelli, Tübingen</i>
11:30 – 11:40 ST 23	Molecular epidemiology of VRE blood culture isolates from a university hospital in Germany <i>T. Holzmann, Regensburg</i>
11:40 – 11:50 ST 24	Plasmid content of MDR Klebsiella pneumoniae clinical isolates as part of the CONTAIN study <i>K. Xanthopoulos, Cologne</i>
11:50 – 12:00 ST 25	Emergence of a highly promiscuous IncN-Plasmid encoding Carbapenemase KPC-2 in a unique genetic environment <i>C. Imirzalioglu, Giessen</i>

12:00 – 13:00 **Lunch Break & Industrial Exhibition**

12:30 – 13:30	Science Slam „Junge Infektiologen“
Ballroom	<i>Vorsitz: C. Lehmann, Cologne</i>
12:30 – 12:42	Beyond antibiotic resistance: what is next? <i>J. Fischer, Cologne</i>
12:42 – 12:54	QuantiFERON: thinking outside the box <i>I. Suárez, Cologne</i>
12:54 – 13:06	European refugee crisis and the onset of an unusual form of severe pneumonia <i>J. Schneider, Munich</i>
13:06 – 13:18	Who's afraid of the Big, Bad - uuhhh - Fomite? <i>U. Seybold, Munich</i>
13:18 – 13:30	Just a cut <i>A. Hölzemer, Hamburg</i>

13:00 – 14:00 **Poster Session II**


Room 3C + D
(3rd level)

14:00 – 14:45 **Infektiologie-Quiz**

Ballroom *S. Hagel, Jena; F. Hanses, Regensburg; N. Jung, Köln;
A. Schneidewind, Bonn; U. Seybold, München*

For your participation in the quiz please scan the following QR code or enter the following link: <http://etc.ch/x83u>





ST = Short Talk

14:45 – 15:15 Plenary Lecture
Ballroom *Chair: A. Lohse, Hamburg*
Science, Policy and Society – Infectious Diseases as an Example
J. Hacker, Halle

15:15 – 15:45 Group Photo / Coffee Break
The Group Photo will be taken in the Reception Hall (ground level).

15:45 – 16:45 Podiumsdiskussion: Bakterielle Resistenzen in Deutschland
Ballroom *Moderation: A. Lohse, Hamburg
L. Wieler, Berlin*
*Podium: U. Fölsch, Kiel; J. Hacker, Halle;
P. Hammann, Frankfurt; R. Müller, Saarbrücken;
U. Rösler, Berlin; K. de With, Dresden*

16:45 – 17:15 Poster Awards and PhD Student Prizes
Ballroom *Doktorandenpreise: S. Herold, Giessen
Posterpreise: U. Protzer, München*

17:15 – 19:15 DGI General Assembly
Ballroom

8:00 – 9:00 Akademie für Infektionsmedizin
Ballroom **Reisemedizin**
G. Burchard, Hamburg

9:00 – 11:00 Symposium VI: Drug Resistance and Control of Tuberculosis and Parasitic Infections
Ballroom *Chairs: P. Kremsner, Tübingen
S. Niemann, Borstel*


9:00 – 9:20 DGI Lecture VI
Drug-resistant tuberculosis
M. Grobusch, Amsterdam/Netherlands

9:20 – 9:30 Variants on chromosome 1p31 protect from latent tuberculosis infection
ST 26 *T. Thye, Hamburg*

9:30 – 9:50 DZIF Lecture VI
Preclinical development of the novel antibiotic Corallopyronin A for filariasis and bacterial infections
A. Hörauf, Bonn

9:50 – 10:00 Biomarkers to diagnose children with malaria in a Plasmodium falciparum endemic region
ST 27 *R. Krumkamp, Hamburg*

10:00 – 10:10 Haematological recovery in African children after treatment with parenteral artesunate for severe malaria
ST 28 *T. Rolling, Hamburg*



10:10 – 10:30 **DZIF Lecture VII**

Emergence of drug resistant TB in Europe
C. Lange, Borstel

10:30 – 10:40 **Preclinical development and metabolism elucidation of BTZ043, an anti-tuberculosis drug candidate**
ST 29
J. Dreisbach, Munich

10:40 – 10:50 **Controlled human malaria infection as a tool to accelerate vaccine and drug development**
ST 30
M. Sulyok, Tübingen

10:50 – 11:00 **The DOs and DON'Ts of atypical MBCs in the context of malaria**
ST 31
S. Portugal, Heidelberg

11:00 – 11:30 **Coffee Break**

11:30 – 11:50 **Preisvortrag „Förderpreis für Klinische Infektionsforschung der DGI“**

Ballroom *Vorsitz: G. Fätkenheuer, Köln*

HIV-associated Lymphoma in the Era of Combination Antiretroviral Therapy
P. Schommers, Köln

11:50 – 13:10 **Symposium VII: Neues zum Thema X – aus der Infektiologie**

Ballroom *Vorsitz: R. Draenert, München
B. Salzberger, Regensburg*

11:50 – 12:10 **Bakterielle Infektionen**
S. Rieg, Freiburg

12:10 – 12:30 **Impfungen**
U. Seybold, München

12:30 – 12:50 **Viruserkrankungen**
A. Schneidewind, Bonn

12:50 – 13:10 **Antibiotika**
F. Hanses, Regensburg

13:10 – 13:20 **Closing Remarks**

Ballroom *R. Horstmann, Hamburg
B. Salzberger, Regensburg*



All poster authors are kindly asked to prepare an electronic version of their poster for the e-poster terminals on site.

Poster Exhibition

The exhibition of the posters nominated for a poster award will take place in the 3rd floor (room 3C+D). Here you will also find the terminals for the electronic posters.

Nominations

Poster authors who are nominated for a poster award shall prepare their posters additionally in DIN A0 size (841 x 1189 mm), portrait format. The dimensions of the poster walls are 1m x 2m, material to fix the posters will be provided. Please provide your poster as well as PDF-file.

All nominated posters should be mounted on Thursday, 28 September 2017, from 10:00 – 12:00. Please remove your poster after the congress on Saturday, 30 September 2017, from 13:20 – 14:20. It is not possible to send remaining posters back to you after the congress. Unfortunately remaining posters have to be disposed of.

Authors nominated for a poster award are kindly asked to be present at their posters during the poster sessions on Thursday, 28 September 2017, from 13:30 – 14:30 and on Friday, 29 September 2017, from 13:00 – 14:00 for questions and discussion.


e-Poster

All electronic posters will be provided at www.dgi-dzif-kongress2017.de in advance.

Poster Awards

The three best posters will be awarded with EUR 500,- each. The presentation of awards will take place on Friday, 29 September 2017, 16:45 – 17:15.

Our sincere thanks go to MSD SHARP & DOHME GMBH for its support.



Abstract Book

The Abstract Book will be available online at the conference website. You will receive a printed copy at the conference.

Contact

COCS GmbH – Congress Organisation C. Schäfer
Felicitas Molnar
Phone +49 (0)89/890677-17
Email: felicitas.molnar@cocs.de

2nd level

DZIF TI-Forum

At the same time of the poster sessions, representatives of the DZIF Translational Infrastructures (TI) will present their services.

DZIF TIs:

- Clinical Trial Unit
- African Partner Institutions
- Biobanking
- Epidemiology
- Bioinformatics
- Pathogen Repository

Take advantage of the opportunity to find out how the TIs can support your research.

The DZIF Academy will also present its programmes. The aim of the DZIF Academy is to educate and train the next generation of researchers in infectious diseases. Highly attractive educational programmes for students and postgraduates are fundamental for excellent basic, translational and clinician scientists.

P = All posters are available as electronic version at the terminals on the 3rd level (room 3C+D).

P** = Posters marked with ** are nominated for a poster award and will be presented additionally on a poster wall within the poster exhibition on the 3rd level (room 3C+D).

SY I: GLOBAL SPREAD OF RESISTANCE

P 1

Analyse des Antibiotikaverbrauchs am Kinderklinikum der Technischen Universität Munich: Angriffspunkte für ein Antibiotic Stewardship Programm

*M. Burggraf*¹, *J. Geisberger*, *K. Kreitmeyer*, *J. Berndt*, *M. Steinhauser*, *N. Rieber*, *U. Behrends*, *J. Hübner*, Munich

*P 2

Intratracheal application of a lytic phage against *Acinetobacter baumannii* pneumonia in mice

*S.-M. Wienhold*¹, *M. Brack*¹, *G. Nouailles*¹, *N. Suttorp*¹, *C. Seitz*², *A. Ross*², *H. Ziehr*², *K. Dieterl*¹, *A. Gruber*¹, *M. Rohde*², *C. Rohde*², *M. Witzenth*¹, ¹Berlin, ²Braunschweig

*P 3

Characterisation of *Neisseria gonorrhoeae* isolates using a core-genome MLST scheme

*P. Higgins*¹, *J. Ertel*¹, *M. Fabri*¹, *C. Lehmann*¹, *M. Parcina*^{1,2}, *C. Schwarze-Zander*^{1,2}, *H. Seifert*¹, ¹Cologne, ²Bonn

P 4

Outcomes of isoniazid resistant TB in patients in Nepal

*F. Freinberger*¹, *H. Hoffmann*², *K. Avsar*², *B. Maharjan*³, *D. Pradhan*³, *B. Shrestha*³, *J. Rupp*⁴, *K. Kranzer*¹, ¹Borstel, ²Gauting, ³Kathmandu/Nepal, ⁴Lübeck

*P 5

Genetic variation and overwintering of *Aedes albopictus* populations from Germany

*A. Heitmann*¹, *R. Lühken*¹, *S. Jansen*^{1,2}, *J. Schmidt-Chanasit*^{1,2}, *J. Börstler*¹, *D. Walther*³, *H. Kampen*⁴, *B. Pluskota*⁵, *I. Ferstl*⁶, *A. Jöst*⁵, *N. Becker*^{5,6}, *E. Tannich*^{1,2}, ¹Hamburg, ²Hamburg-Luebeck-Borstel, ³Muencheberg, ⁴Greifswald, ⁵Speyer, ⁶Heidelberg

P 6

Toward Validating the Pathblocker Concept: Lead Generation and Optimization of PqsR Antagonists for the Treatment of Chronic *Pseudomonas aeruginosa* Infections

M. Emptyng, *C. Lu*, *C. Maurer*, *M. Zender*, *A. Thomann*, *A. de Mello Martins*, *R. Hartmann*, Saarbrücken

P 7

***Mycoplasma genitalium* demonstrates high levels of antibiotic resistance in Australia**

*S. Bone*¹, *L. Tan*¹, *S. Walker*¹, *J. Su*², *C. Bradshaw*², *C. Fairley*², *S. Garland*², *E. Mokany*¹, *S. Tabrizi*², ¹Sydney/Australia, ²Melbourne/Australia

P 8

cfr-Gen vermittelte Mehrfachresistenz bei Staphylokokken aus dem Nutztiersektor und das Risiko der Übertragung auf den Menschen

*C. Cuny*¹, *W. Witte*¹, *P. Arnold*², ¹Wernigerode, ²Echternach/Luxembourg

*P 9

A retrospective analysis of paediatric inpatient data on antibiotic use in a teaching hospital in The Gambia

P. Chaw^{1,2}, *K. Schlinkmann*^{1,2}, *H. Raupach-Rosin*¹, *A. Karch*^{1,2}, *J. Hübner*³, *R. Mikolajczyk*^{1,4}, ¹Braunschweig, ²Hanover, ³Munich, ⁴Halle (Saale)

P 10

Emergence of ceftazidime-avibactam non-susceptibility in a multidrug resistant *Klebsiella pneumoniae* isolate

A. Both, *H. Büttner*, *J. Huang*, *M. Perbandt*, *C. Belmar Campos*, *M. Christner*, *F. Maurer*, *S. Kluge*, *C. König*, *M. Aepfelbacher*, *D. Wichmann*, *H. Rohde*, Hamburg

*P 11

Highly conserved plasmids drive the spread of the mobile colistin resistance gene *mcr-1* in Germany and Spain

*L. Falgenhauer*¹, *Y. Yao*¹, *H. Ghosh*¹, *S. Doijad*¹, *S.-E. Waezsada*¹, *K. Gwozdziński*¹, *J. Schmiedel*¹, *M. Fritzenwanker*¹, *N. Roschanski*², *U. Roesler*², *A. Irrgang*², *A. Käsbohrer*^{2,3}, *R. Bauerfeind*¹, *C. Ewers*⁴, *A. Schiffmann*¹, *G. Michael*⁵, *S. Schwarz*², *B. Bunk*⁴, *C. Spröer*⁴, *A. Goesmann*¹, *J. Overmann*⁴, *N. Prim*⁵, *A. Rivera*⁵, *B. Mirelis*⁵, *C. Imirzalioglu*¹, *T. Chakraborty*¹, ¹Giessen, ²Berlin, ³Vienna/Austria, ⁴Braunschweig, ⁵Barcelona/Spain

P 12

Comparative analysis of ESBL-producing *E. coli* isolated from environment, fish, livestock and humans in Mwanza/Tanzania

*S. Mshana*¹, *L. Falgenhauer*², *N. Moremi*¹, *J. Seni*¹, *H. Ghosh*², *C. Imirzalioglu*², *T. Chakraborty*², ¹Mwanza/Tanzania, ²Gießen

*P 13

Rapid identification of carbapenem-resistant *Acinetobacter baumannii* with a novel immunochromatographic lateral flow assay

*S. Mertins*¹, *P. Higgins*¹, *Q. Gillemann*², *P. Mertens*², *H. Seifert*¹, *M. Krönke*¹, *A. Klimka*¹, ¹Cologne, ²Gembloux/Belgium

P 14

Biosynthesis of capsular polysaccharides as target for antibiotics

M. Rausch, *H. Ulm*, *H.-G. Sahl*, *F. Grein*, *T. Schneider*, Bonn

*P 15

Rapid emergence of highly variable and transferable oxazolidinone and phenicol transporter *OprA* in German clinical *Enterococcus* spp.

J. Bender, *C. Fleige*, *D. Lange*, *U. Geringer*, *I. Klare*, *G. Werner*, Wernigerode

P 16**ASA³P: An automatic and highly scalable pipeline for bacterial genome assembly, annotation and higher-level analyses**

O. Schwengers, M. Schneider, A. Hoek, Y. Yao, H. Ghosh, M. Fritzenwanker, S. Doijad, L. Falgenhauer, T. Hain, T. Chakraborty, A. Goesmann, Gießen

P 17**A novel medium for the improved detection of *mcr-1*-producing *Enterobacteriaceae***

K. Gwozdziński, L. Falgenhauer, C. Imirzalioglu, T. Chakraborty, Gießen

P 18**Molecular epidemiology of multidrug resistant tuberculosis in Germany 1995-2016**

M. Merker¹, T. Kohl¹, R. Diehl², S. Andres¹, C. Lange¹, K. Kranzer¹, S. Niemann¹, ¹Borstel, ²Kiel

P 19**HCV Resistance Profile Evolution in a GT1b, DAA-naïve Patient before, on and after Failing Triple DAA Therapy**

E. Knops¹, N. Schübel², E. Heger¹, R. Kaiser¹, S. Inden¹, P. Kalaghatg³, S. Sierra¹, ¹Cologne, ²Osnabrück, ³Saarbrücken

P 20**A novel subclone of ST131 C1/H30R harboring *bla*_{CTX-M-27} in clinical isolates emerging in Germany**

H. Ghosh, S. Doijad, L. Falgenhauer, M. Fritzenwanker, O. Schwengers, C. Imirzalioglu, T. Chakraborty, Contain Study Group, RESET Study Group, Giessen

P 21**Selten, aber divers - *cf*-vermittelte Linezolidresistenz bei *S. aureus***

F. Layer¹, C. Kehrenberg², J. Bender¹, G. Werner¹, B. Strommenger¹, ¹Wernigerode, ²Hanover

P 22*Ebola Virus persistence in seminal fluid of Ebola virus disease survivors: a longitudinal study and evidence for sexual transmission during the resurgence of the disease in Guinea in 2016**

S. Duraffour¹, D. Sissoko², B. Diallo³, R. Kerber¹, L. Oestereich¹, J. Guedj⁴, T. Nguyen⁴, P. Formenty⁵, S. Keita³, D. Malvy², X. Anglaret^{2,6}, S. Günther¹, ¹Hamburg, ²Bordeaux/France, ³Conakry/Guinea, ⁴Paris/France, ⁵Geneva/Switzerland, ⁶Abidja/Côte d'Ivoire

P 23**Molecular characterization of extended-spectrum beta-lactamase-producing *Enterobacteriaceae* in asylum-seekers in Rhineland-Palatinate, 2016-2017**

Y. Pfeifer¹, L. Ehlkes^{2,3,4}, G. Werner¹, T. Eckmanns³, M. Vogt², P. Zanger^{2,5}, J. Walter³, ¹Wernigerode, ²Landau, ³Berlin, ⁴Stockholm/Sweden, ⁵Heidelberg

P 24**Pathogens and antimicrobial resistance in patients with travelers' diarrhea presenting at a German tertiary care center.**

T. Brehm, M. Addo, T. Rolling, C. Vinnemeier, Hamburg

SY II: NOVEL ANTIVIRAL TREATMENT STRATEGIES**P 25****Resident alveolar macrophages are depleted early upon influenza virus infection and cell death correlates positively with neutrophil recruitment**

C. Malainou, C. Peteranderl, W. Seeger, J. Lohmeyer, S. Herold, Gießen

P 26*Antiretroviral Treatment Initiation and Guideline Adherence in the German ClinSurv HIV Cohort between 1999-2016: Assessing the Impact of the START Trial in Germany**

M. Stecher¹, D. Schmidt², C. Kollan², B. Günsenheimer-Bartmeyer², C. Lehmann¹, M. Platten¹, G. Fätkenheuer¹, J. Vehreschild¹, ¹Cologne, ²Berlin

P 27*IFN-free DAA therapy does not fully re-constitute the altered phenotype and function of HCV-specific CD8+ T cells but immune check-point inhibitions can selectively re-invigorate the functionality during chronic HCV**

A. Aregay, K. Deterding, M. Manns, M. Cornberg, S. Owusu Sekyere, H. Wedemeyer, Hanover

P 28**A new antiviral approach – Inhibition of RNA viruses depending on eIF4A-dependent translation by the natural compound Silvestrol**

C. Müller¹, F. Schulte², N. Biedenkopf², S. Becker², J. Ziebuhr¹, R. Hartmann², A. Grünweller², ¹Gießen, ²Marburg

P 29**Suppressive capacity of PMN-MDSC is lost in advanced stages of HIV-1 infection**

E. Grütznert, A. Neizert, R. Stirner, R. Conca, I. Andrä, M. Schiemann, C. Klein, U. Protzer, J. Bogner, R. Draenert, Munich

P 30*Establishment of a single-point assay to evaluate the relationship of molecular structure and antiviral activity of cationic amphiphilic drugs**

A.-P. Gunesch¹, F. Zapatero-Belinchon¹, M. Manns¹, E. Steinmann¹, M. Brönstrup², T. von Hahn¹, ¹Hanover, ²Braunschweig

P 31*Different prevalences of HCV resistance-associated substitutions within NS5A of genotype 4 and implications for treatment**

J. Dietz¹, S. Susser¹, J. Vermehren¹, K.-H. Peiffer¹, T. Welzel¹, B. Müllhaupt², K. Wursthorn³, J. Petersen³, J. Schattenberg⁴, J.-P. Chave⁵, C. Niederau⁶, R. Schmid⁷, J. von Felden³, J. Schulze zur Wiesch⁸, C. Moreno⁹, T. von Hahn⁹, T. Berg¹⁰, C. Berg¹¹, S. Zeuzem¹, C. Sarrazin^{1,12}, ¹Frankfurt am Main, ²Zürich/Switzerland, ³Hamburg, ⁴Mainz, ⁵Lausanne/Switzerland, ⁶Oberhausen, ⁷Munich, ⁸Brüssel/Belgium, ⁹Hanover, ¹⁰Leipzig, ¹¹Tübingen, ¹²Wiesbaden

P 32

West Nile virus and Usutu virus monitoring of wild birds in Germany

*F. Michel*¹, *U. Ziegler*¹, *M. Eiden*¹, *M. Keller*¹, *C. Fast*¹, *G. Dobler*², *M. Groschup*¹, ¹Greifswald-Insel Riems, ²Munich

*P 33

Sensitizing *Staphylococcus aureus* to cationic anti-microbial peptides

*A. Jorge*¹, *U. Bilitewski*^{2,3}, *A. Peschel*¹, ¹Tübingen, ²Braunschweig, ³Hanover

P 34

Host proteases as potential target for anti-viral therapy to influenza A infections

K. Schughart^{1,2,3}, *R. Lambert*^{1,2}, ¹Braunschweig, ²Hanover, ³Memphis/USA

P 35

Enabling anti-viral adoptive T cell therapy from seronegative individuals

T. Müller, *M. Effenberger*, *K. Schober*, *D. Busch*, Munich

P 36

Modulation of the host cell response to treat Lassa Fever

L. Oestereich, *D. Wozniak*, *E. Pallasch*, *S. Bockholt*, *C. Munoz-Fontela*, *S. Günther*, Hamburg

*P 37

Targeted AAV-mediated Delivery of HIV-1 LTR-specific Recombinase Brec1

*J. Breuer*¹, *N. Beschorner*², *J. Hauber*², *H. Büning*¹, *F. Buchholz*³, ¹Hanover, ²Hamburg, ³Dresden

P 38

Development of small molecule inhibitors targeting TRAF protein binding to the LMP1 oncoprotein of Epstein-Barr virus

*F. Giehler*¹, *D. Weid*², *M. Ostertag*¹, *K. Schorpp*¹, *S. Dornauer*¹, *H. Kutz*¹, *K. Sterz*¹, *B. Biesinger-Zwosta*², *K. Hadian*¹, *J. Kirchmair*³, *G. Popowicz*³, *A. Kieser*¹, ¹Munich, ²Erlangen, ³Hamburg

*P 39

Assessing off-target activity of a novel TALEN targeting the HIV co-receptor CCR5

L. Schwarze, *U. Mock*, *B. Fehse*, Hamburg

*P 40

High throughput reporter screen to identify inhibitors of clinically relevant human polyomavirus infections

E. Kraus, *N. Fischer*, *A. Grundhoff*, Hamburg

*P 41

Non-immunosuppressive cyclosporin A derivatives as broad-spectrum coronavirus inhibitors

*D. Bairad*¹, *S. Schwinghammer*¹, *Y. Ma-Lauer*¹, *B. von Brunn*¹, *M. Müller*², *D. Muth*^{2,3}, *C. Drosten*^{2,3}, *A. von Brunn*¹, ¹Munich, ²Bonn, ³Berlin

P 42

Screening for antivirals targeting the human cytomegalovirus alkaline nuclease using a high-throughput system

T. Potgieter, *A. Caceres-Nuñez*, *E. Ostermann*, *W. Brune*, Hamburg

P 43

Analysis of the IFN-alpha treatment response, HCC risk and mortality of HDV infected patients at different levels of HDV replication

*J.-H. Bockmann*¹, *M. Lütgehetmann*¹, *J. Blöcker*¹, *J. Von Felden*¹, *M. Wehmeyer*¹, *K. Giersch*¹, *C. Scheurich*¹, *M. Dandri*¹, *S. Lüth*², *A. Lohse*¹, *J. Schulze zur Wiesch*¹, ¹Hamburg, ²Neuruppin

P 44

Chronische Norovirusinfektionen nach Nierentransplantation - Risikofaktoren und Therapieoption mit Immunglobulinen

C. Struve, *A. Bienholz*, *S. Doff*, *U. Eisenberger*, *J. Korth*, *B. Wilde*, *O. Witzke*, *H. Guberina*, Essen

*P 45

Decision Making of Accurate HIV-1 Post Exposure Prophylaxis Prescription

M. Scholten, *I. Suárez*, *D. Gillor*, *M. Platten*, *T. Kümmerle*, *G. Fätkenheuer*, *C. Lehmann*, Cologne

P 46

Human cytomegalovirus infections after Hematopoietic Stem Cell Transplantation: correlation of serum cytokine levels and variations in the HCMV genome population with clinical outcomes

P. Kay-Fedorov, *P. Varanasi*, *J. Zischke*, *A. Dhingra*, *A. Heim*, *C. Falk*, *E. Mischak-Weissing*, *T. Ganzenmüller*, Hanover

P 47

Crystal structure of Zika virus NS2B-NS3 protease facilitates design of antivirals

*R. Hilgenfeld*¹, *L. Zhang*¹, *G. Hansen*¹, *C. Nitsche*², *C. Klein*², *W. Rut*³, *M. Drag*³, *J. Lei*¹, ¹Lübeck, ²Heidelberg, ³Wroclaw/Poland

P 48

alpha-Ketoamides as broad spectrum inhibitors of coronavirus and enterovirus replication

*L. Zhang*¹, *D. Lin*¹, *Y. Kusov*¹, *Q. Ma*¹, *Y. Nian*², *J. Wang*², *H. Liu*², *P. Leyssen*³, *K. Lanko*³, *J. Neyts*³, *A. de Wilde*⁴, *E.J. Snijder*⁴, *R. Hilgenfeld*¹, ¹Lübeck, ²Shanghai/China, ³Leuven/Belgium, ⁴Leiden/Netherlands

SY III: IMMUNOTHERAPIES AND VACCINES

P 49

Partial depletion of regulatory T cells improve the immune response after vaccination against tuberculosis

*F. Varela*¹, *I. Ogunsulire*¹, *J. Behrends*¹, *E.-M. Agger*², *M. Almanan*³, *D. Hildeman*³, *C. Hölscher*¹, ¹Borstel, ²Copenhagen/Denmark, ³Cincinnati/USA

P 50

Interleukin-23 promotes the recruitment of protective multifunctional CD4 T cells after subunit *Mycobacterium tuberculosis* vaccination independently of interleukin-17A

*K. Ritter*¹, *J. Behrends*¹, *E.-M. Agger*², *C. Hölscher*^{1,3}, *H. Erdmann*¹, ¹Borstel, ²Copenhagen/Denmark, ³Kiel

P 51

A novel QuantiFERON based test for detection of neutralizing IFN- γ autoantibodies in patients with severe opportunistic infections*I. Suarez, C. Lehmann, H. Gröll, J. Gräß, M. Kochanek, G. Fätkenheuer, G. Plum, P. Hartmann, J. Rybniker, Cologne*

*P 52

Reconstitution of HIV-, MTB- and CMV-specific T-cell functionality in children on antiretroviral therapy is associated with shifts in memory phenotype and decreased PD1-expression*M. Muenchhoff¹, E. Adland², T. Ndung'u³, P. Goulder^{2,3}, ¹Munich, ²Oxford/United Kingdom, ³Durban/South Africa*

P 53

Sensitizing Staphylococcus aureus to cationic antimicrobial peptides by MprF-inhibiting monoclonal antibodies*C. Slavetinsky¹, C. Ernst¹, A. Kraus², A. Geyer¹, A. Peschel¹, ¹Tübingen, ²Martinsried*

P 54

Duration of protection from pneumonia and antibody kinetics in pneumococcal vaccination of hemodialysis patients (DOPPIO)*S. Mellinghoff, V. Dimitriou, A. Steinbach, G. von Gersdorff, B. Liss, O. Cornely, Cologne*

P 55

Whole cell lysate as antigen source for the differential analysis of experimental vaccines against newly emerging infections*O. Pinkenburg¹, V. Czudai-Matwich¹, A. Fiedler², M. Mühlebach², M. Matrosovich¹, S. Becker¹, M. Lohoff¹, ¹Marburg, ²Langen*

P 56

Immunogenetics of Ebola virus disease*P. Ruibal¹, A. Lüdtker¹, L. Oestereich¹, B. Becker-Ziaja¹, S. Gómez-Medina¹, M. Rottstegge¹, D.M. Wozniak¹, T. Rieger¹, G. Xiaojiang^{2,3}, M. Carrington^{2,3}, F. Feng⁴, K. Sawatzki², T.B. Kepler⁴, S. Günther¹, C. Muñoz-Fontela¹, ¹Hamburg, ²Frederick/USA, ³Cambridge/USA, ⁴Boston/USA*

*P 57

KIR3DS1, an activating NK cell receptor implicated in HIV-1 disease, binds differentially to distinct forms of HLA-F*A. Hölzemer¹, C. Dulberger², J. Chukwukelu¹, G. Martrus Zapater¹, E. Adams², M. Altfeld¹, ¹Hamburg, ²Chicago/USA*

P 58

Targeting novel surface associated proteins for vaccination against Staphylococcus aureus*A. Klimka, A. Nicolai, S. Mertins, F. Becker, O. Krut, M. Krönke, Cologne*

P 59

Impact of immunosuppressive drugs on the BK-Polyomavirus Non Coding Control Region (NCCR) activity*J. Korth, B. Wilde, S. Ciesek, J. Verheyen, A. Brinkhoff, U. Dittmer, A. Kribben, O. Witzke, M. Widera, Essen*

P 60

The DZIF Transplant Cohort e.V*D. Schindler, Members of the DZIF Transplantation Cohort e.V., Munich*

*P 61

Peptide vaccination against cytomegalovirus (CMV) induces cellular immune responses in CMV seronegative endstage renal disease patients*C. Sommerer, A. Schmitt, T. Giese, P. Schnitzler, M. Zeier, M. Schmitt, Heidelberg*

P 62

Kidney transplant recipients show humoral response to 13-valent conjugate pneumococcal vaccine*S. Hecke, M. Lindemann, B. Wilde, P. Horn, S. Dolff, A. Bienholz, U. Eisenberger, O. Witzke, Essen*

P 63

Modifying the ggtree Function to Visualize IgG Recognition Strength of Peptide Variants in the Context of their Phylogenetic Relationship*V. Hoffmann¹, G. Pollakis², M. Ahmed¹, K. Held¹, C. Geldmacher¹, ¹Munich, ²Liverpool/United Kingdom*

P 64

Increased phosphorylation of p70S6 kinase is associated with CMV reactivation in lung transplant patients*M. Meier, V. Besa, M. Cherneha, S. Dolff, A. Bienholz, H. Guberina, B. Wilde, O. Witzke, Essen*

P 65

Dual role of antigen-presenting cells during Ebola virus infection*E. Nelson¹, N. Hertoghs², A. Ludtke¹, S. Gunther¹, S. Krasemann¹, J. Idoyaga³, L. Oestereich¹, T. Geijtenbeek², C. Muñoz-Fontela¹, ¹Hamburg, ²Amsterdam/Netherlands, ³Stanford/USA*

P 66

Associations between individual gut microbiota signatures and the activation of an adaptive immune response to anti-PD-L1 immunotherapy in patients with metastatic melanoma*A. Tsakmaklis¹, R. Hartel¹, M. von Bergwelt¹, H. Schlösser¹, M. Schlaak¹, C. Mauch¹, F. Farowski¹, M. Cruz Aguilar¹, P. Oefner², P. Higgins¹, M. Vehreschild¹, ¹Cologne, ²Regensburg*

P 67

Prophylactic and Therapeutic Potential of Antisera against Acute Viral Infections*R. Schmidt¹, O. Dolnik², A. Volz³, G. Sutter³, V. von Messling¹, ¹Langen, ²Marburg, ³Munich*

P 68

Experimental performance evaluation and threshold recommendations for MHC class I binding prediction tools*M. Bonsack, S. Hoppe, J. Winter, R. Blatnik, A. Riemer, Heidelberg*

*P 69

Cytomegalovirus reactivation prior to acute graft-versus-host disease leads to fast immune reconstitution and overall survival*P. Varanasi¹, J. Ogonek¹, E. Dammann¹, S. Luther¹, P. Schweier¹, M. Stadler¹, A. Ganser¹, M. Messerle¹, C. Falk¹, S. Borchers², L. Hambach¹, E. Weissinger¹, ¹Hanover, ²Heidelberg*

P 70**Increased expression of the coinhibitors PD-1 and BTLA on CMV-specific T-cells is associated with symptomatic CMV infection in renal transplant patients**

B. Wilde, J. Reinold, J. Korth, M. Sun, S. Doff, A. Bienholz, C. Struve, H. Guberina, P. Horn, M. Lindemann, O. Witzke, Essen

P 71**Evaluation of synthetic self-replicating RNAs expressing Ebola virus proteins**

V. Krähling¹, S. Erbar², A. Vogel², S. Witzel², B. Tillmann², T. Beisser², U. Sahin², S. Becker¹, ¹Marburg, ²Mainz

P 72*Efficient clearance of gram-positive and negative bacteria by human iPSC derived phagocytes**

A. Rafiei, A. Hashtchin, M. Ackermann, H. Kempf, C. Hesse, M. Bickes, M. Hetzel, M. Kühnel, A. Schambach, S. Wronski, T. Moritz, R. Zweigerdt, D. Viemann, A. Munder, N. Lachmann, Hanover

P 73**Eingeschränkte Wirksamkeit der quadrivalenten Meningokokken-Impfung bei Patienten mit atypischem hämolytisch-urämischem Syndrom und Therapie mit dem Komplementinhibitor Eculizumab**

A. Bienholz¹, S. Doff¹, H. Guberina¹, B. Wilde¹, U. Vogel², H. Claus², A. Kribben¹, O. Witzke¹, ¹Essen, ²Würzburg

P 74**Human miRNome profiling identifies a microRNA signature induced by the Ebola vaccine rVSV-ZEBOV**

T. Fischer^{1,2}, C. Dahlke^{1,2}, M. Spohn¹, L. Burkhard¹, F. Olearo¹, M. Ly^{1,2}, M. Zinser¹, R. Kasonta^{1,2}, A. Rechten^{1,2}, H. Stubbe³, S. Borregaard¹, A. Jambrecina¹, A. Grundhoff¹, M. Addo^{1,2}, ¹Hamburg, ²Hamburg-Lübeck-Borstel-Riems, ³Munich

P 75**Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes**

A. Volz, A. Freudenstein, L. Marr, G. Sutter, Munich

P 76*Dominant low avidity clonotypes arise from reverse TCR repertoire evolution during chronic CMV infection**

K. Schober¹, F. Voit¹, S. Grassmann¹, T. Müller¹, J. Eggert¹, L. Cicin-Sain^{2,3}, V. Buchholz¹, D. Busch¹, ¹Munich, ²Braunschweig, ³Hanover

P 77*Immune regulatory mechanisms in acute HIV-1 infection**

H. Stubbe¹, K. Mücke¹, A. Jablonka², M. Stecher³, R. Stirner¹, R. Conca¹, U. Kastenbauer¹, R. Pauli¹, N. Postel¹, C. Spinner¹, E. Wolf¹, G. Behrens², J. Vehreschild³, J. Bogner¹, R. Draenert¹, ¹Munich, ²Hanover, ³Cologne

P 78**Development of a new strategy to target intracellular infections with *Leishmania major*: from a natural compound to synthetic derivatives**

S. Choy¹, H. Bernin¹, S. Lender¹, E. Bifeld¹, Y. Fujimoto², T. Aiba², K. Fukase³, N. Gonzalez-Roldan⁴, J. Clos¹, H. Lotter¹, ¹Hamburg, ²Yokohama/Japan, ³Osaka/Japan, ⁴Borstel

P 79**Humanized mice reconstituted with mature T and B cells for testing novel immune modulatory strategies against Epstein-Barr-Virus infection and lymphoma**

S. Danisch¹, A. Cornelius¹, C. Slabik¹, S. Theobald¹, M. Albanese², R. Zeidler², W. Hammerschmidt², R. Stripecke¹, ¹Hanover, ²Munich

P 80**Efficacy testing of a newly developed MVA-based vaccine against Ebola virus in a mouse model**

A. Kupke¹, A. Volz², E. Dietzel¹, J. Schmidt¹, H. Shams-Eldin¹, L. Sauerhering¹, M. Gellhorn Serra¹, C. Herden³, M. Eickmann¹, S. Becker¹, G. Sutter², ¹Marburg, ²Munich, ³Gießen

P 81**HCMV infection of mice reconstituted with the human immune system reveals anatomical sites of reactivation by optical imaging analyses and modulation of T and B cell maturation in lymphatic tissues**

S. Theobald¹, V. Volk¹, H. Olbrich¹, S. Lienenklaus¹, A. Bleich¹, D. Schaudien¹, P. Riese², C. Guzman², R. Stripecke¹, ¹Hanover, ²Braunschweig

P 82*Homeostatic and antigenic support by induced dendritic cells expressing gB amplifies the activation gB-CAR T cells for post-transplant immunotherapy against HCMV**

H. Olbrich¹, S. Theobald¹, M. Mamonkin², R. Stripecke¹, ¹Hanover, ²Houston/USA

P 83**Illuminating the in vivo tropism of Modified Vaccinia virus Ankara in infected chicken embryos**

M. Langenmayer, A. Lülff, S. Adam-Neumeier, G. Sutter, A. Volz, Munich

P 84**Recombinant Modified Vaccinia virus Ankara vaccines delivering G and F antigens of Nipah Virus**

S. Veit, A. Freudenstein, A. Volz, G. Sutter, Munich

P 85**Development of an Epstein-Barr virus (EBV) epitope quality scoring system for clinical application**

D. Adhikary¹, A. Cirac¹, R. Poirey², H.-J. Delecluse², J. Mautner¹, U. Behrends¹, ¹Munich, ²Heidelberg

P 86**Distribution of Ebola virus RNA in organs of vaccinated mice: an in situ hybridization study**

M. Gellhorn Serra¹, A. Kupke¹, E. Dietzel¹, A. Volz², G. Sutter², S. Becker¹, ¹Marburg, ²Munich

P 87**Increased expression of the coinhibitors PD-1 and BTLA on CMV-specific T-cells is associated with symptomatic CMV infection in renal transplant patients**

B. Wilde, J. Reinold, S. Doff, A. Bienholz, C. Struve, H. Guberina, P. Horn, M. Lindemann, O. Witzke, Essen

P 88*Testing the efficacy of a Measles Virus-derived Zika virus vaccine in a Zika challenge model of pregnant mice**

C. Nürnberger, B. Bodmer, A. Fiedler, M. Mühlebach, Langen

SY IV: MICROBIOME AND INFECTION

P 89

HLA-B27-restricted CTL-escape mutations increase sensitivity of HIV-1- to Interferon α *P. Schommers*¹, *C. Ford*², *A. Hölzemer*², *G. Fätkenheuer*¹, *M. Altfeld*², ¹Cologne, ²Hamburg

P 90

Delay in Adequate Antibiotic Therapy Results in Fatal Disease Outcome in a Mouse Model of CAP*S. Berger*, *C. Gökeri*, *U. Behrendt*, *S.-M. Wienhold*, *J. Lienau*, *N. Suttorp*, *M. Witzernath*, *G. Nouailles*, Berlin

P 91

C26 - a novel compound inhibiting the expression of type III secretion system 1 of *Salmonella* Typhimurium*I. Grin*¹, *A. Naini*², *M. Riess*¹, *M. Brönstrup*², *S. Wagner*¹, ¹Tübingen, ²Braunschweig

P 92

Quality control and assurance of biosamples collected within the frame of the Transplant cohort in DZIF*A. Kühn*¹, *N. Klopp*², *L. Sandmann*², *F. Schlott*¹, *S. Engelhardt*¹, *S. Kukolka*¹, *H. Nitschko*¹, *J. Haedicke-Jarboui*³, *C. Sommerer*⁴, *N. Metzendorf*⁴, *T. Weis*⁴, *D. Schindler*¹, *P. Schirmacher*⁴, *C. Gieger*¹, *G. Anton*¹, ¹Munich, ²Hanover, ³Tuebingen, ⁴Heidelberg

P 93

Viral infection dynamics of entomobirnavirus Culex Y virus and the immune response elicited in mosquito cells*M. Leggewie*¹, *K. Franzke*², *S. Jansen*¹, *S. Vattipally*³, *E. Tannich*¹, *S. Becker*⁴, *E. Schnettler*^{1,3}, ¹Hamburg, ²Greifswald, ³Glasgow/United Kingdom, ⁴Hanover

P 94

HIV-1-mediated downmodulation of HLA-C impacts target-cell recognition and antiviral activity of NK cells*C. Körner*¹, *C. Simoneau*², *P. Schommers*^{1,3}, *M. Granoff*², *M. Ziegler*¹, *A. Hölzemer*¹, *S. Lunemann*¹, *J. Chukwukelu*¹, *B. Corleis*², *V. Naranbhai*^{2,4}, *D. Won*^{2,5}, *E. Scully*^{2,6}, *S. Jost*^{2,5}, *F. Kirchhoff*⁷, *M. Carrington*^{2,4}, *M. Altfeld*¹, ¹Hamburg, ²Cambridge/USA, ³Cologne, ⁴Frederick/USA, ⁵Boston/USA, ⁶Baltimore/USA, ⁷Ulm

P 95

Characterisation of the Zika virus induced small RNA response in *Aedes aegypti* cells*M. Varjak*¹, *C. Donald*¹, *T. Mottram*¹, *S. Vattipally*¹, *A. Merits*², *K. Maringer*³, *E. Schnettler*⁴, *A. Kohl*¹, ¹Glasgow/United Kingdom, ²Tartu/Estonia, ³Guildford/United Kingdom, ⁴Hamburg

P 96

Deep rectal swabs for microbiome sampling and analysis in a cohort study of hematological and oncological patients*L. Biehl*^{1,2}, *D. Garzett*³, *F. Farowski*¹, *D. Ring*³, *M. Koeppl*³, *H. Rohde*², *P. Schafhausen*², *B. Stecher*³, *M.J. Vehreschild*¹, ¹Cologne, ²Hamburg, ³Munich

P 97

Novel approach to capture and enrich *Mycobacterium tuberculosis* and its DNA from saliva*J. Hansen*¹, *K. Kolbe*^{1,2}, *S. Malm*¹, *J. Zallett*¹, *D. Hillemann*¹, *K.-H. Wiesmüller*³, *J. Brandenburg*¹, *C. Herzmann*¹, *N. Reiling*¹, ¹Sülfeld, ²Bethesda/USA, ³Tübingen

P 98

Neoglycopeptides as potential Shiga toxin inhibitors*G. Pohlentz*¹, *J. Mühling*¹, *P. Dersch*², *H. Karch*¹, ¹Münster, ²Braunschweig

P 99

Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients is Associated with Protracted Cold Ischemic Time of Seropositive Donor Organs*F. Schlott*¹, *K. Katsirntak*², *D. Steubl*¹, *W. Puppe*², *D. Hoffmann*¹, *C. Blume*², *U. Heemann*¹, *H. Haller*², *L. Renders*¹, *D. Busch*¹, *C. Falk*², *M. Neuenhahn*¹, ¹Munich, ²Hanover

P 100

Establishment and optimisation of a mouse model for EHEC- and Shiga toxin- mediated pathogenesis*S. Mühlen*, *A. Rolof*, *P. Dersch*, Braunschweig

P 101

Transcriptional, proteomic and metabolic networks of the Fur and PerR regulated iron and carbon-starvation metabolism of *Clostridium difficile**A.-M. Michel*, *M. Berges*, *M. Neumann-Schaal*, *D. Jahn*, Braunschweig

P 102

Mode of action of the protein VapA of *Rhodococcus equi* on phagosome membranes*C. Nehls*¹, *A. Haas*², *J. Bürck*³, *K. Komorowski*¹, *T. Gutsmann*¹, ¹Borstel, ²Bonn, ³Karlsruhe

P 103

A Comparative Study on Techniques for the Determination of Lipid Bilayer Permeabilization*L. Paulowski*¹, *N. Gebauer*¹, *J. Wernecke*^{1,2}, *B. Cornell*³, *T. Gutsmann*¹, ¹Borstel, ²Hamburg, ³Sydney/Australia

P 104

High malaria positivity as well as high prevalence of infections due to gram-positive bacteria and arthropod-borne infections in febrile outpatients attending a rural hospital in Southwestern Tanzania*N. Heinrich*¹, *J. Dreisbach*¹, *O. Geisenberger*¹, *B. Flach*¹, *C. Mangu*², *L. Sud*², *L. Maboko*², *H. Schimanowski-Thomson*³, *C. Mwansongela*², *G. Dobler*¹, *M. Hölscher*¹, *C. Scheiber*¹, ¹Munich, ²Mbeya/Tanzania, ³Matema/Tanzania

P 105

Leptin signaling regulates macrophage mediated inflammatory responses against *Salmonella* Typhimurium through mTORC2*J. Fischer*, *S. Gutiérrez*, *R. Ganesan*, *M. Wolke*, *J. Cassens*, *J. Brüning*, *P. Hartmann*, *G. Plum*, *N. Robinson*, Cologne

P 106**Evaluation of Data Accuracy of the Surveillance Outbreak Response Management and Analysis System (SORMAS)**

*S. Toikkanen*¹, *S. Glöckner*¹, *A. Olawunmi*², *C. Ameh*², *J. Benzler*³, *G. Kirchner*³, *G. Poggensee*², *D. Tom-Aba*¹, *G. Krause*¹, ¹Braunschweig, ²Abuja/Nigeria, ³Berlin

SY V: RESISTANCE IN NOSOCOMIAL INFECTIONS***P 107****Implementierung von Antibiotic stewardship an einem Haus der Grund- und Regelversorgung: Konzept und Ergebnisse**

*M. Bonsignore*¹, *E. Balamitsa*¹, *C. Nobis*¹, *C. Geffers*², *I. Nachtigal*², ¹Gelsenkirchen, ²Berlin

P 108**Antibiotic Stewardship auf einer neurologischen Intensivstation an einem Universitätsklinikum**

C. Blei, *A. Dudakova*, *H. Eiffert*, *S. Scheithauer*, *U. Groß*, *J. Liman*, *K. Hein*, *M. Schulze*, Göttingen

P 109**Studies on the Resistance Mechanism of the Novel Topoisomerase Inhibitor Cystobactamid**

K. Cirniski^{1,2}, *J. Herrmann*^{1,2}, *G. Testolin*^{2,3}, *S. Hütte*^{2,3}, *N. Zaboranyi*^{1,2}, *M. Stadler*^{2,3}, *M. Brönstrup*^{2,3}, *R. Müller*^{1,2}, ¹Saarbrücken, ²Hanover, ³Braunschweig

P 110**Mechanism-of-Action of the Cyclic Depsipeptide Antibiotic Telomycin**

F. Hennessen^{1,2}, *J. Herrmann*^{1,2}, *A. Abou Fayad*^{1,2}, *K. Cirniski*^{1,2}, *H.-P. Prochnow*^{2,3}, *A. Bauer*⁴, *J. Pippe*^{2,3}, *W. Blankenfeldt*^{2,3}, *M. Brönstrup*^{2,3}, *R. Müller*^{2,3}, ¹Saarbrücken, ²Hanover, ³Braunschweig, ⁴Frankfurt am Main

P 111**Multilayer network modelling of hospital infections**

A. Jarynowski^{1,2}, *A. Grabowski*³, *D. Marchewka*², ¹Wroclaw/Poland, ²Krakow/Poland, ³Warsaw/Poland

P 112*Fluoroquinolone non-susceptibility in 3rd generation cephalosporin resistant Enterobacteriaceae in German university hospitals**

*A. Rohde*¹, *J. Zweigner*², *M. Wiese-Posselt*¹, *H. Seifert*², *P. Gastmeier*¹, *W. Kern*³, *S. Athos*^{1,2,3,4,5,6}, ¹Berlin, ²Cologne, ³Freiburg, ⁴Lübeck, ⁵Tübingen, ⁶Munich

P 113*Early bacterial colonization and antibiotic resistance gene acquisition in newborns**

*H. Slevogt*¹, *T. Klassert*¹, *S. Kankel*¹, *M. Stock*¹, *C. Zubiria-Barrera*¹, *N. Doehring*², *D. Fischer*², ¹Jena, ²Frankfurt/Main

P 114**Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2009 to 2016, data from the German Antibiotic Resistance Surveillance System (ARS)**

U. Koppe, *A. von Laer*, *I. Noll*, *M. Feig*, *M. Abu Sin*, *T. Eckmanns*, Berlin

P 115**Co-resistance of Carbapenem non-susceptible Klebsiella pneumoniae to other classes of antibiotics in hospitals from 2009 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS)**

U. Koppe, *A. von Laer*, *I. Noll*, *M. Feig*, *M. Abu Sin*, *T. Eckmanns*, Berlin

P 116**Inzidenz und Risikofaktoren für Blutstrominfektionen bei Intensivpatienten mit großflächigen Verbrennungen: eine monozentrische retrospektive Kohortenstudie**

*A. Fochtmann-Frana*¹, *C. Freystätter*¹, *V. Vorstandlechner*¹, *A. Barth*¹, *M. Bolliger*¹, *E. Presterl*¹, *G. Ibra*¹, *G. Muschitz*¹, *M. Mittlböck*¹, *A. Makrithis*¹, *T. Rath*¹, *C. Radtke*¹, *C. Forstner*^{1,2}, ¹Vienna/Austria, ²Jena

P 117*Nitroxoline in geriatric patients with lower urinary tract infection fails to achieve microbiological eradication despite clinical improvement: a non-comparative, prospective observational study**

C. Forstner^{1,2}, *A. Kwetkat*¹, *O. Makarewicz*¹, *A. Hartung*¹, *W. Pster*¹, *H. Stefan*¹, *N. Harrison*², *U. Schumacher*¹, *M. Pletz*¹, ¹Jena, ²Vienna/Austria

P 118*Stellen die zunehmenden Nachweise von MRSA CC398 als Hospitalkeim bei Pferden ein Risiko für deren Kontaktpersonen dar?**

*C. Cuny*¹, *W. Witte*¹, *M. Abdelbary*², *F. Layer*¹, *G. Werner*¹, ¹Wernigerode, ²Lausanne/Switzerland

P 119**Two-tier approach combining molecular and culture-based techniques for optimized detection of vancomycin-resistant enterococci**

A. Both, *G. Franke*, *N. Miwald*, *M. Christner*, *M. Lütgehetmann*, *E.-M. Klupp*, *C. Belmar Campos*, *H. Büttner*, *M. Aepfelbacher*, *H. Rohde*, Hamburg

P 120**Limiting spread of vancomycin-resistant enterococci (VRE) by applying probiotics to patients receiving antibiotics**

*S. Borgmann*¹, *B. RieB*¹, *B. Jürgens*¹, *R. Siegmund*¹, *G. Werner*², *I. Klare*², ¹Ingolstadt, ²Wernigerode

P 121*Electronic medication systems simplify antimicrobial prescription review by clinical pharmacists and facilitate complex antimicrobial stewardship interventions**

C. Sommer, *F. Olearo*, *J. Jochum*, *H. Hilgarth*, *J. Katchanov*, *C. Langebrake*, *M. Baehr*, *A.W. Lohse*, *F. Maurer*, Hamburg

P 122**Preclinical development of HY-133, a recombinant phage lysin for rapid decolonization of Staphylococcus aureus from nasal habitats**

*E. Idelevich*¹, *S. Molinaro*², *S. Eisele*³, *B. Krismer*⁴, *C. Weidenmaier*⁴, *L. Heitmann*⁵, *G. Winter*³, *T. Hesterkamp*⁵, *W. Mutter*², *K. Becker*¹, *A. Peschel*⁴, ¹Münster, ²Bernried, ³Munich, ⁴Tübingen, ⁵Braunschweig

★P 123

Diversity of porin loss and β -lactamase presence in carbapenem resistant *Klebsiella pneumoniae*
*L. Biniössek*¹, *S. Gerson*¹, *K. Xanthopoulou*¹, *J. Ertel*¹, *M. Kaase*², *H. Seifert*¹, *P. Higgins*¹, ¹Cologne, ²Bochum

★P 124

Bloodstream Infection due to Multidrug-Resistant Organisms – Multicenter Study on Determinants of Clinical Outcomes (BLOOMY.COM)
*S. Eisenbeis*¹, *A. Mischnik*², *M. Buhl*¹, *S. Peter*¹, *J. Falgenhauer*³, *N. Kaeding*^{4,5}, *A. Rohde*⁶, *M. Vehreschild*⁷, *T. Chakraborty*⁸, *P. Gastmeier*⁸, *J. Rupp*^{4,5}, *H. Seifert*^{7,8}, *W. Kern*², *E. Tacconelli*¹, *F. Hölzl*¹, ¹Tübingen, ²Freiburg, ³Giessen, ⁴Lübeck, ⁵Hamburg-Lübeck-Borstel, ⁶Berlin, ⁷Cologne, ⁸Bonn

★P 125

Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis
D. Baur, *B.P. Gladstone*, *F. Burkert*, *E. Carrara*, *F. Foschi*, *S. Döbele*, *E. Tacconelli*, Tübingen

★P 126

Novel clone of *Serratia marcescens* associated with neonatal outbreaks in Germany: A novel subspecies?
*S. Doijad*¹, *Y. Yao*¹, *L. Falgenhauer*¹, *M. Fritzenwanker*¹, *H. Ghosh*¹, *K. Gwozdziński*¹, *R. Hilker*¹, *O. Schwengers*¹, *B. Abt*², *B. Bunk*², *S. Reuter*³, *C. Imirzalioglu*¹, *P. Gastmeier*⁴, *A. Kola*⁴, *A. Goesmann*¹, *J. Overmann*², *H. Grundmann*³, *T. Chakraborty*¹, ¹Gießen, ²Braunschweig, ³Freiburg, ⁴Berlin

SY VI: DRUG RESISTANCE AND CONTROL OF TUBERCULOSIS AND PARASITIC INFECTIONS

P 127

Trypanosoma cruzi escapes elimination through the induction of co-inhibitory receptors on T cells
R. Grote-Gálvez, *T. Jacobs*, Hamburg

P 128

Inhibition of neutrophil myeloperoxidase controls M. tuberculosis induced-necrosis and growth after phagocytosis by macrophages
*T. Dallenga*¹, *U. Repnik*², *R. Reimer*^{1,3}, *G. Griffiths*², *U. Schaible*¹, ¹Borstel, ²Oslo/Norway, ³Hamburg

P 129

TB SEQUEL: Pathogenesis and risk factors of long-term pulmonary sequelae defining the individual outcome and public health impact of TB disease
*A. Rachow*¹, *N. Bhatt*², *B. Kampmann*³, *N. Ntinginya*⁴, *I. Sanne*⁵, *K. Lonnroth*⁶, *S. Niemann*⁷, *R. Wallis*⁸, *M. Hoelscher*¹, *G. Churchyard*⁶, ¹Munich, ²Maputo/Mozambique, ³Banjul/Gambia, ⁴Mbeya/Tanzania, ⁵Johannesburg/South Africa, ⁶Geneva/Switzerland, ⁷Borstel

P 130

Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells
*I. Kroidl*¹, *M. Chachage*², *J. Mnkai*², *A. Nsojo*², *M. Berninghoff*¹, *L. Maganga*², *J. Verweij*³, *A. Hoerauf*¹, *N. Ntinginya*², *P. Clowes*², *M. Hoelscher*¹, *E. Saathoff*¹, *C. Geldmacher*¹, ¹Munich, ²Mbeya/Tanzania, ³Tilburg/Netherlands, ⁴Bonn

P 131

Concurrent helminth infection interferes with vaccine-induced protection against influenza virus infection
W. Hartmann, *N. Kruse*, *G. Gabriel*, *M.-L. Brunn*, *M. Breloer*, Hamburg

P 132

Distribution of the Usutu virus and its impact on bird populations in Germany
*R. Lühken*¹, *S. Thomas*², *H. Jöst*¹, *N. Tjaden*², *U. Ziegler*³, *M. Groschup*³, *C. Beierkuhnlein*², *J. Schmidt-Chanasit*¹, ¹Hamburg, ²Bayreuth, ³Riems

P 133

Preclinical development of the novel antibiotic Corallopyronin A for filariasis and bacterial infections
*A. Hoerauf*¹, *A. Schiefer*¹, *A. Krome*¹, *S. Bouhired*¹, *S. Kehraus*¹, *K. Wagner*¹, *M. Stadler*², *R. Jansen*², *M. Roth*³, *R. Müller*⁴, *T. Schäberle*¹, *G. König*¹, *K. Pfarr*¹, ¹Bonn, ²Braunschweig, ³Jena, ⁴Saarbrücken

P 134

Towards a structural and functional model of the PfEMP1 mediated host-pathogen interactions for the development of novel treatment options against malaria
L. Ehnold, *N. Mohr*, *F. Geisinger*, *S. Ofori*, *L. Roth*, *I. Bruchhaus*, *S. Witt*, Hamburg

P 135

Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible tuberculosis: a systematic review and meta-analysis
*B. Lange*¹, *C. Kodama*^{2,3}, *I. Olaru*⁴, *P. Khan*², *M. Lipman*², *J. Seddon*², *D. Sloan*⁵, *L. Grandjean*², *R. Ferrand*², *K. Kranzer*^{2,4}, ¹Freiburg, ²London/United Kingdom, ³Geneva/Switzerland, ⁴Borstel, ⁵St Andrews/United Kingdom

★P 136

Novel TB immune-diagnostic test (TAM-TB) allows for treatment monitoring in a rare case of tuberculous coxitis
M. Ahmed, *I. Dubinsky*, *K. Held*, *C. Geldmacher*, *U. von Both*, Munich

★P 137

Ending the diagnostic dilemma in TB: proposing better study designs to validate new diagnostics
*L. Olbrich*¹, *U. von Both*¹, *U. Behrends*¹, *S. Niemann*², *C. Geldmacher*¹, *K. Avsar*³, *M. Seilmaier*¹, *M. Steinhauser*¹, *H. Hoffmann*³, *M. Hoelscher*¹, *N. Heinrich*¹, ¹Munich, ²Borstel, ³Gauting

P 138

Laboratory implementation of Next Generation Sequencing for medium and high throughput whole genome analysis of clinical M. tuberculosis complex strains
V. Mohr, *J. Zallet*, *T. Ubben*, *C. Hahn*, *T. Struve-Sonnenschein*, *A. Lüdemann*, *V. Schleusener*, *K. Kranzer*, *C. Utpatel*, *T. Kohl*, *S. Niemann*, Borstel

P 139

Analytical Quantification Techniques for Corallopyronin A - suitable for different stages of its development
A. Krome, *S. Bouhired*, *S. Kehraus*, *A. Schiefer*, *K. Pfarr*, *A. Hoerauf*, *K. Wagner*, *G. König*, Bonn

P 140**Human iPSC-derived macrophages as a tool to study the susceptibility to mycobacterial infections**

K. Haake^{1,2}, *J. Lam*¹, *A.-L. Neehus*¹, *M. Ackermann*¹, *S. Merkert*¹, *M. Schubert*¹, *C. Happle*¹, *U. Martin*¹, *U. Baumann*¹, *A. Schambach*¹, *J. Bustamante*², *J. Roesler*³, *N. Lachmann*¹, ¹Hanover, ²Paris/France, ³Dresden

P 141**The treatment of Multi-Drug-Resistant Tuberculosis (MDR-TB) patients in Gabon: Implementation of the short course regimen (9 months), interim results**

J. Edoa^{1,2}, *U. Ateba-Ngoa*^{1,2}, *M. Massinga-Loembe*^{1,2}, *D. Madiou*¹, *R. Adegbite*^{1,2}, *S. Gould*^{1,2}, *G. Rossatanga*¹, *A. Mfoumbi*^{1,2}, *C. Mevyan*^{1,2}, *J. Mahoumbou*³, *A. Alabi*^{1,2}, *B. Lell*^{1,2}, *P. Kreamsner*^{1,2}, *A. Adegnika*^{1,2}, *M. Grobusch*^{1,2,4}, ¹Lambaréné/Gabon, ²Tübingen, ³Libreville/Gabon, ⁴Amsterdam/Netherlands

P 142**Usage of RNAi-based trigger gene silencing to identify pathogenicity factors of *Entamoeba histolytica* involved in amoebic liver abscess formation**

S. Lender, *J. Matthiesen*, *H. Fehling*, *M. Meyer*, *H. Lotter*, *I. Bruchhaus*, Hamburg

P 143**Interaction Between Host Defence Peptides and Mycobacteria**

*C. Nehls*¹, *L. Paulowski*¹, *S. Willcocks*², *N. Reiling*¹, *U. Schaible*¹, *T. Gutschmann*¹, ¹Borstel, ²London/United Kingdom

P 144*Corticosteroids potently abrogate RIPK1-independent necrosis of Mycobacterium tuberculosis – implications for host-directed therapies**

*J. Gräß*¹, *E. van Gumpel*¹, *S. Winter*¹, *A. Cato*², *C. Hölscher*³, *J. Rybniker*¹, ¹Cologne, ²Karlsruhe, ³Borstel

P 145*Neutrophil proteins as potential signatures for point-of-care diagnostic and putative targets for host-directed-therapy in tuberculosis**

*C. Leschczyk*¹, *T. Dallenga*¹, *K. Laxmikanth*², *V. Sparr*¹, *B. Karlsdorf*¹, *A. Sickmann*², *U. Schaible*¹, ¹Borstel, ²Dortmund

P 146**Numerical chest X-ray score can be used as a predictive factor in treatment of tuberculosis**

*S. Konsten*¹, *P. Phillips*², *N. Ntinginya*³, *L. Minja*⁴, *K. Reither*⁵, *G. Kibiki*⁶, *I. Sanne*⁷, *K. Mellet*⁷, *A. Diacon*⁸, *R. Dawson*⁹, *G. Churchyard*⁷, *A. Nunn*², *A. Colbers*¹⁰, *A. Mekota*¹, *S. Gillespie*¹¹, *M. Boeree*¹⁰, *R. Aarnoutse*¹⁰, *M. Hoelscher*¹, *N. Heinrich*¹, ¹Munich, ²London/United Kingdom, ³Mbeya/Tanzania, ⁴Bagamoyo/Tanzania, ⁵Basel/Switzerland, ⁶Moshi/Tanzania, ⁷Johannesburg/South Africa, ⁸Tygerberg/South Africa, ⁹Cape Town/South Africa, ¹⁰Nijmegen/Netherlands, ¹¹St Andrews/United Kingdom

P 147**Impact of naturally acquired immunity to *P. falciparum* on var gene expression in controlled human malaria infections**

*A. Bachmann*¹, *E. Bruske*², *R. Krumkamp*¹, *L. Turner*³, *J.S. Wichers*¹, *M. Petter*¹, *B.K.L. Sim*⁵, *S.L. Hoffman*⁵, *P. Kreamsner*², *M. Frank*², *B. Lell*⁶, *T. Lavstsen*³, *B. Mordmüller*², *E. Tannich*¹, ¹Hamburg, ²Tübingen, ³Copenhagen/Denmark, ⁴Erlangen, ⁵Rockville/USA, ⁶Lambaréné/Gabon

P 148*Evaluation of BTZ043 in the standard mouse model of tuberculosis infection and a novel model reflecting human pathology**

*K. Walter*¹, *N. Heinrich*², *J. Dreisbach*², *J. Kokesch-Himmelreich*³, *A. Römpf*³, *M. Hölscher*², *C. Hölscher*¹, ¹Borstel, ²Munich, ³Bayreuth

P 149**The IL-23/IL-17-axis negatively regulates the IL-13- and Ly6C^{lo} monocyte-dependent tissue regeneration during hepatic amebiasis**

*J. Noll*¹, *E. Helk*¹, *H. Fehling*¹, *H. Bernin*¹, *T. Jacobs*¹, *T. Ernst*¹, *H. Ittrich*¹, *C. Hölscher*², *H. Lotter*¹, ¹Hamburg, ²Sülfeld

P 150*The role of intracellular pH for chloroquine action and resistance in *Plasmodium falciparum***

J. Wunderlich^{1,2}, ¹Berlin, ²Montreal/Canada

P 151*Identification of *Plasmodium falciparum* erythrocyte membrane protein 1 (PfEMP1) molecules involved in the interaction with various human endothelial receptors**

L. Roth, *N. Metwally*, *A.-K. Tilly*, *M. Dörpinghaus*, *P. Lubiana*, *S. Witt*, *E. Tannich*, *I. Bruchhaus*, Hamburg

P 152**Changes in the transcriptome of human brain endothelial cells (HBECs) due to a *Plasmodium falciparum* malaria infection**

M. Dörpinghaus, *F. Fürstenwerth*, *L. Roth*, *N. Galal Metwally*, *P. Lubiana*, *E. Tannich*, *T. Jacobs*, *I. Bruchhaus*, Hamburg

P 153*Development of a Therapeutic Drug Monitoring platform for personalized treatment of patients with M/XDR-TB**

*H. Karakose*¹, *N. Köhler*¹, *C. Lange*^{1,2,3,4}, *P. Sanchez-Carballo*¹, *D. Schwudke*¹, ¹Borstel, ²Windhoek/Namibia, ³Lübeck, ⁴Stockholm/Sweden

P 154*A longitudinal molecular epidemiological study of tuberculosis in Hanover**

*P. Beckert*¹, *M. Yilmaz*², *A. Hanke-Lensing*², *M. Bliemeister*², *S. Gerdes*^{1,2}, *S. Niemann*¹, ¹Borstel, ²Hanover

P 155**A five years molecular epidemiological study of tuberculosis in Lambaréné, Gabon - Investigation of outbreak strains.**

*P. Beckert*¹, *E. Bruske*², *S. Bélard*^{2,3,4,5}, *A. Traoré*^{3,6}, *D. Kombila*³, *H. Lay*², *J. Frick*², *S. Janssen*^{3,4,7}, *T. Kohl*¹, *B. Lell*^{2,3}, *P. Kreamsner*^{2,3}, *M. Frank*², *A. Alabi*³, *M. Grobusch*^{2,4,7}, *S. Niemann*¹, ¹Borstel, ²Tuebingen, ³Lambaréné/Gabon, ⁴Amsterdam/Netherlands, ⁵Berlin, ⁶Thohoyandou/South Africa, ⁷Cape Town/South Africa

P 156**Profiling the expression dynamics of virulence-associated genes in clinical *Plasmodium falciparum* isolates**

*J. Wichers*¹, *J. Scholz*¹, *H. von Thien*¹, *S. Lorenzen*¹, *M. Petter*², *M. Duffy*³, *E. Tannich*¹, *A. Bachmann*¹, ¹Hamburg, ²Erlangen, ³Melbourne/Australia

P 157**Development of a high resolution MALDI imaging method for the characterization of Mycobacterium tuberculosis (Mtb) pathology**

J. Kokesch-Himmelreich¹, A. Fatangare¹, K. Walter², J. Dreisbach³, N. Heinrich³, M. Hölscher³, C. Hölscher², A. Römpf¹, ¹Kulmbach, ²Borstel, ³Munich

P 158**Autoantibodies as biomarkers to diagnose children with *P.falciparum* malaria**

N. Struck¹, R. Krumkamp¹, T. Jacobs¹, D. Winter¹, M. Zimmermann¹, D. Eibach¹, L. Reigl¹, E. Owusu-Dabo², J. May¹, ¹Hamburg, ²Kumasi/Ghana

P 159**Identification and characterization of parasite phospholipases involved in *Plasmodium falciparum* egress from red blood cells**

P.-C. Burda, F. Nkrumah, H. Matthiesen, T.-W. Gilberger, Hamburg

P 160**The dry season reservoir of *P. falciparum* infection and a possible sensing mechanism**

C. Andrade¹, S. Doumbo², L. Djibo², C. Anderson¹, S. Li³, D. Doumtabe², C. Martens⁴, S. Porcella⁴, O. K. Doumbo², K. Kayentao², A. Ongoiba², B. Traore², P. Crompton³, S. Portugal¹, ¹Heidelberg, ²Bamako/Mali, ³Rockville, Maryland/USA, ⁴Hamilton, Montana/USA

P 161**Inflammatory marker response during the dry season reservoir of *P. falciparum* infection**

C. Anderson¹, S. Doumbo², L. Djibo², C. Andrade¹, S. Li³, D. Doumtabe², O. Doumbo², K. Kayentao², A. Ongoiba², B. Traore², P. Crompton³, S. Portugal¹, ¹Heidelberg, ²Bamako/Mali, ³Maryland/USA

P 162**Viszerale Leishmaniose bei einem HIV+-Patienten**

S. Jansen, H. Guberina, S. Doff, D. Föhring, S. Esser, O. Witzke, Essen

P 163**The molecular nature of the potent T-cell antigen: the molecule of the old tuberculin skin test and its molecular promiscuity.**

C. Magana, C. Kallenberg, C. Huebner, Y.H. Song, Lübeck

P 164*Treatment of lymphatic filariasis and onchocerciasis – current and new therapeutic approaches**

U. Klarmann-Schulz¹, L. Batsa-Debrah², K. Pfarr¹, J. Osei-Mensah², A. Schiefer¹, A. Debrah², A. Hoerauf¹, ¹Bonn, ²Kumasi/Ghana

P 165**Human genetic variant affecting calcium pump expression in red blood cells impedes parasite growth and protects from severe malaria**

C. Strauss, K. Schuld, T. Thye, G. Ruge, J. Sievertsen, B. Muntau, R. Horstmann, C. Timmann, Hamburg

VARIA (KLINISCHE INFEKTOLOGIE)

P 166*Resistenzsituation bei ambulant erworbener unkomplizierter Harnwegsinfektion in Deutschland 2015 (SARHA-Studie)**

A. Klingenberg¹, N. Willrich¹, M. Feig¹, I. Noll¹, K. Oberdorfer², A. Krenz-Weinreich³, D. Emrich¹, E. Zill¹, W. Kalka-Moll⁴, T. Eckmanns¹, ¹Berlin, ²Heidelberg, ³Plön, ⁴Mönchengladbach

P 167**Transient suppression of pro-inflammatory T-cell subsets during experimental endotoxemia in healthy men**

A. Brinkhoff, A. Sieberichs, H. Engler, S. Doff, S. Benson, J. Korth, M. Schedlowski, A. Kribben, B. Wilde, O. Witzke, Essen

P 168**Einfluss von Diabetes mellitus (Typ 2) auf Inzidenz und Verlauf einer spontan bakteriellen Peritonitis bei Patienten mit Leberzirrhose und Aszites**

T. Tergast¹, H. Laser¹, M. Manns^{1,2}, M. Cornberg^{1,2}, B. Maasoumy^{1,2}, ¹Hanover, ²Braunschweig

P 169**Dosisabhängige Effekte von Protonenpumpeninhibitoren auf den Verlauf einer spontan bakteriellen Peritonitis**

T. Tergast¹, H. Laser¹, A. Wranke¹, M. Manns^{1,2}, M. Cornberg^{1,2}, B. Maasoumy^{1,2}, ¹Hanover, ²Braunschweig

P 170*Implementation of a Standard Diet Regimen for Neutropenic High Risk Cancer Patients: Effects on Incidence of Infections, Foodborne Diseases, and Outcome**

C. Jakob¹, A. Löhnert^{1,2}, M. Stecher^{1,2}, O. Cornely¹, J. Vehreschild^{1,2}, ¹Cologne, ²Bonn

P 171**Causes of severe febrile illness in hospitalized children, Nouna Burkina Faso**

C. Dah¹, M. Seynou¹, S. Gies², J. Kompenhans², R. Sorgho², A. Sié¹, B. Coulibaly¹, R. Sauerborn², A. Soares², ¹Nouna/Burkina Faso, ²Heidelberg

P 172*Experimental transmission of Zika virus by mosquitoes from Central Europe***

A. Heitmann¹, S. Jansen¹, R. Lühken¹, M. Leggewie¹, M. Badusche¹, B. Pluskota², N. Becker^{2,3}, O. Vapalahti⁴, J. Schmidt-Chanasit¹, E. Tannich¹, ¹Hamburg, ²Speyer, ³Heidelberg, ⁴Helsinki/Finland

P 173**Anti-metabolic effects of first-choice antimicrobials against *C. trachomatis***

N. Schmidt, M. Wanker, N. Käding, K. Shima, J. Rupp, Lübeck

P 174**"Gut vs butt": Comparative analysis of the HIV reservoir size in distinct CD4+ T cell subsets in the terminal ileum, rectum, and peripheral blood of HIV-1 positive patients**

C. Horn, M. Augustin, J. Rybniker, D. Nierhoff, I. Suarez, M. Platten, S.-H. Chon, M. Ercanoglu, C. Lehmann, Cologne

P 175*Fetal metabolic stress disrupts immune homeostasis and induces pro-inflammatory responses in HIV-1 and cART-exposed infants**

N. Schoeman¹, G. Moutloatse², A. Harms¹, H. Scherpbier³, R. Vreeken¹, L. van Leeuwen³, C. Reinecke², T. Kuijpers³, R. Berger¹, T. Hankemeier¹, M. Bunders⁴, ¹Leiden/Netherlands, ²Potchefstroom/South Africa, ³Amsterdam/Netherlands, ⁴Hamburg

P 176**Specialized tissue sample collectives for the DZIF Tx-cohort – a pilot study**

B. Stottmeier¹, F. Lasitschka¹, K. Heeg¹, D. Schindler², C. Gieger², P. Schirmacher¹, ¹Heidelberg, ²Munich

P 177*Maßnahmen zur Prävention der Postsplenektomie-Sepsis – Ergebnisse der prospektiven Freiburger Asplenie-Registerstudie**

L. Bechet¹, C. Theilacker^{1,2}, B. Lange¹, K. Stete¹, M. Müller¹, M.-F. Juzek-Küpper^{1,3}, I. Joost¹, W. Kern¹, S. Rieg¹, ¹Freiburg, ²Paris/France, ³Aachen

P 178*Host factors of primary CMV infection in patients after kidney transplantation**

C. Sommerer^{1,2}, M. Neuenhahn¹, C. Falk^{1,3}, T. Giese^{1,2}, ¹Munich, ²Heidelberg, ³Hanover

P 179*Is CD32 a marker of infected cells and can be used to characterize the HIV reservoir?**

M. Wittner, G. Dunay, S. Kummer, V. Schlicker, A.-D. Hüfner, O. Degen, J. Eberhard, J. Schulze zur Wiesch, Hamburg

P 180**Biomarker analysis of a Nigerian Lassa Fever cohort**

L. Oestereich¹, E. Speranza², D. Wozniak¹, J. Port¹, B. Becker-Ziaja³, E. Pallasch¹, S. Bockholt¹, D. Asogun⁴, E. Ogbaini-Emovon⁴, M. Pahlmann¹, J. Connor², C. Munoz-Fontela¹, S. Günther¹, ¹Hamburg, ²Boston/USA, ³Berlin, ⁴Irrua/Nigeria

P 181*Immune monitoring-supported treatment of a pediatric patient with sequential GvHD, acute rejection and CMV infection following lung transplantation**

C. Falk, N. Schwerk, C. Müller, I. Tudorache, K. Daemen, J. Keil, C. Neudoer, G. Hansen, A. Haverich, G. Warnecke, Hanover

P 182*Fast Point of Care Testing for Common Uropathogens and Antibiotic Resistances in Urological Urine Samples to Aid Antibiotic Stewardship**

M. Fritzenwanker^{1,2}, M. Grabitz^{1,2}, O. Schwengers^{1,2}, P. Hrouska¹, B. Arnetz¹, C. Imirzalioglu^{1,2}, F. Wagenlehner^{1,2}, T. Chakraborty^{1,2}, ¹Gießen, ²Gießen-Marburg-Langen,

P 183**Lymphocyte Homing and Transmission in acute Lassa Fever**

J. Port¹, D. Wozniak¹, M. Rottstegge¹, E. Ogbaini-Emovon², S. Günther¹, L. Oestereich¹, C. Muñoz-Fontela¹, ¹Hamburg, ²Irrua/Nigeria

P 184**Berlin's Fast Track Cities Initiative – Where are we now?**

D. Schmidt, C. Kollan, M. an der Heiden, H. Jessen, B. Gunsenheimer-Bartmeyer, V. Bremer, Berlin

P 185**A blind passenger rat in an aircraft: Establishment of a workflow for multiple pathogen detection**

E. Heuser¹, F. Doss², S. Holtfreter³, D. Mrochen³, A. Zautner⁴, R. Ryll¹, M. Beer¹, R. Ulrich¹, ¹Greifswald-Insel Riems, ²Berlin, ³Greifswald, ⁴Göttingen

P 186*HLA-E allelic variants impact on occurrence of CMV infection after living renal transplantation**

H. Guberina, F. de Nardi Silva, R. Tomoya Michita, S. Doff, A. Bienholz, F. Heinemann, B. Wilde, M. Trilling, P. Horn, A. Kribben, O. Witzke, V. Rebmann, Essen

P 187**JCV-Ausscheidung im Urin von HIV-1-infizierten Patienten**

T. Harrer, K. Korn, B. Spriewald, E. Harrer, Erlangen

P 188**Clinical chemistry and haematology study in Lassa-fever positive patients at ISTD, Nigeria**

M. Pahlmann¹, B. Becker-Ziaja², L. Oestereich¹, R. Krumkamp¹, E. Pallasch¹, D. Adomeh³, Y. Ighodal³, J. Oyakhilome³, E. Omomoh³, T. Olorok³, J. Agbukur³, E. Uyigwe³, E. Mudebonam³, D. Asogun³, S. Günther¹, ¹Hamburg, ²Berlin, ³Irrua/Nigeria

P 189**The Munich Infectious Mononucleosis (IMMUC) Study on Biomarkers and Causative Factors of Complicated and/or Protracted Symptomatic EBV Primary Infection**

L. Schulte-Hillen¹, C. Meindl¹, J. Geisberger¹, F. Fischer¹, J. Mücke¹, S. Strunz¹, N. Körber¹, T. Bauer¹, S. Fink², M.-H. Tsai², H.-J. Delecluse², J. Mautner¹, F. Hauck¹, D. Hoffmann¹, P. Luppa¹, M. Steinborn¹, W. Hammerschmidt¹, C. Falk³, T. Schulz³, N. Rieber¹, M. Steinhauser¹, A. Moosmann¹, D. Adhikary¹, U. Draenert¹, S. Eger¹, A. Hapfelmeier¹, A. Nieters⁴, U. Behrends¹, ¹Munich, ²Heidelberg, ³Hanover, ⁴Freiburg

P 190**Epidemiology, clinical course and laboratory features of leptospirosis in returning travellers at a Northern German infectious disease center 2011 - 2017.**


T. Brehm, J. Schulze zur Wiesch, M. Addo, A. Lohse, S. Schmiedel, Hamburg

P 191**Improvement of a tissue maceration technique for the determination of placental involvement in Schistosomiasis**

B. Schleenvoigt¹, M. Holtfreter², H. Neubauer¹, T. Groten¹, H. El-Adawy¹, J. Pastuschek¹, J. Richter², D. Häussinger², M. Pletz¹, ¹Jena, ²Düsseldorf

P 192**Performing timely blood cultures for infectious patients is associated with shorter duration of therapy and reduced length of stay**

C. Luz¹, J.-W. Dik¹, A. Friedrich¹, J. van der Palen², S. van Assen³, P. Nannan Panday¹, B. Sinha¹, ¹Groningen/Netherlands, ²Enschede/Netherlands, ³Emmen/Netherlands



A

Addo, M. p. 8, p. 12
 Adhikary, D. p. 31
 Ahmed, M. p. 37
 Altfeld, M. p. 11, p. 12
 Anderson, C. p. 40
 Andrade, C. p. 40
 Aregay, A. p. 25
 Autenrieth, I. p. 13

B

Bachmann, A. p. 38
 Bairad, D. p. 26
 Beckert, P. p. 39
 Behrends, U. p. 43
 Bender, J. p. 23
 Berger, S. p. 32
 Biehl, L. p. 32
 Biniossek, L. p. 36
 Bockmann, J. p. 27
 Bone, S. p. 22
 Bonsack, M. p. 29
 Bonsignore, M. p. 34
 Borgmann, S. p. 35
 Both, A. p. 23, p. 35
 Brehm, T. p. 24, p. 43
 Breloer, M. p. 37
 Breuer, J. p. 26
 Brinkhoff, A. p. 41
 Brönstrup, M. p. 10
 Bunders, M. p. 42
 Burchard, G. p. 12, p. 17
 Burda, P. p. 40
 Burggraf, M. p. 22
 Busch, D. p. 11

C

Chaw, P. p. 23
 Choy, S. p. 30
 Cirnski, K. p. 34
 Cuny, C. p. 23, p. 35

D

Dallenga, T. p. 36
 Danisch, S. p. 31
 de With, K. p. 16
 Dietz, J. p. 25
 Dojjad, S. p. 36
 Dolff, S. p. 30
 Dörpinghaus, M. p. 39
 Draenert, R. p. 8, p. 18
 Dreisbach, J. p. 18
 Duraffour, S. p. 24

E

Eberhard, J. p. 11
 Edoa, J. p. 38
 Edoa, J. p. 38
 Eibach, D. p. 36
 Empting, M. p. 9, p. 22

F

Falgenhauer, L. p. 23
 Falk, C. p. 42
 Farowski, F. p. 13
 Fätkenheuer, G. p. 18
 Fischer, J. p. 15, p. 33
 Fischer, T. p. 30
 Fölsch, U. p. 16
 Ford, C. p. 32
 Forstner, C. p. 35
 Freinberger, F. p. 22
 Fritzenwanker, M. p. 42

G

Gellhorn Serra, M. p. 31
 Ghosh, H. p. 24
 Giehler, F. p. 26
 Giese, T. p. 42
 Grin, I. p. 32
 Grobusch, M. p. 17
 Grote-Gálvez, R. p. 36
 Grützner, E. p. 25
 Guberina, H. p. 11, p. 43
 Gunesch, A. p. 25
 Gutschmann, T. p. 38
 Gwozdziński, K. p. 24

H

Haake, K. p. 38
 Hacker, J. p. 16
 Hagel, S. p. 15
 Hammann, P. p. 16
 Hansen, J. p. 33
 Hanses, F. p. 15, p. 18
 Hardtke, S. p. 10
 Harrer, T. p. 43
 Hauser, A. p. 9
 Heckel, S. p. 29
 Heitmann, A. p. 22
 Hennessen, F. p. 34
 Herold, S. p. 5, p. 16
 Higgins, P. p. 22
 Hilgenfeld, R. p. 10, p. 27
 Hofer, S. p. 8
 Hoffmann, R. p. 8
 Hoffmann, V. p. 29
 Holler, E. p. 13
 Hölischer, C. p. 5, p. 11, p. 27
 Hölzemer, A. p. 5, p. 15, p. 28
 Hölzl, F. p. 5, p. 13
 Holzmann, T. p. 14
 Hörauf, A. p. 17, 37
 Horn, C. p. 41
 Horstmann, R. p. 19

I

Imirzalioglu, C. p. 14

J

Jahn, D. p. 33
 Jakob, C. p. 41
 Jansen, S. p. 40
 Jansen, St. p. 41
 Jarynowski, A. p. 34
 Jorge, A. p. 26
 Jung, N. p. 15

K

Karakose, H. p. 39
 Kay-Fedorov, P. p. 27
 Kern, W. p. 14
 Klarmann-Schulz, U. p. 40

Klein, F. p. 10
 Klimka, A. p. 28
 Klingeberg, A. p. 41
 Klöckner, A. p. 9
 Knops, E. p. 9
 Koch, T. p. 11
 Koeppel, M. p. 13
 Kokesch-Himmelreich, J. p. 40
 Kompenhans, J. p. 41
 Konsten, S. p. 38
 Koppe, U. p. 34, p. 35
 Körner, C. p. 32
 Korth, J. p. 28
 Krähling, V. p. 30
 Kraus, E. p. 26
 Kreamsner, P. p. 17, p. 18
 Kroidl, I. p. 26
 Krome, A. p. 37
 Krönke, M. p. 9
 Krumkamp, R. p. 17
 Kühn, A. p. 32
 Kupke, A. p. 31

L

Lange, B. p. 37
 Lange, C. p. 18
 Layer, F. p. 24
 Leggewie, M. p. 32
 Lehmann, C. p. 10, p. 15
 Lender, S. p. 38
 Leszczczyk, C. p. 38
 Lohse, A. p. 8, p. 16
 Lühken, R. p. 37
 Luz, C. p. 43

M

Malainou, C. p. 25
 Maurer, F. p. 14
 May, J. p. 8
 Meier, M. p. 29
 Mellinghoff, S. p. 28
 Merker, M. p. 24
 Mertins, S. p. 23
 Michel, F. p. 26
 Mohr, V. p. 37
 Montoya-Díaz, E. p. 11
 Muenchhoff, M. p. 28

Mühlen, S. p. 33
Müller, C. p. 25
Müller, R. p. 11, p. 16
Müller, T. p. 26

N

Nehls, C. p. 33
Nelson, E. p. 29
Ni, Y. p. 10
Niemann, S. p. 12, p. 17
Noll, J. p. 39
Nordmann, P. p. 8
Nürnberger, C. p. 31

O

Oestereich, L. p. 26, p. 42
Olbrich, H. p. 31
Olbrich, L. p. 37
Olearo, F. p. 35

P

Pagel, J. p. 13
Pahlmann, M. p. 43
Paulowski, L. p. 33
Peschel, A. p. 35
Pfeifer, Y. p. 24
Pinkenburg, O. p. 28
Platten, M. p. 10
Pohlentz, G. p. 33
Port, J. p. 42
Portugal, S. p. 18
Potgieter, T. p. 26
Protzer, U. p. 26

R

Rachow, A. p. 36
Rafiei Hashtchin, A. p. 30
Rausch, M. p. 23
Reinold, J. p. 31
Rieg, S. p. 18, p. 42
Ritter, K. p. 27
Rohde, A. p. 34
Rolling, T. p. 17
Rösler, U. p. 16
Roth, L. p. 39

Rottstegge, M. p. 11
Ruibal, P. p. 28
Rybniker, J. p. 28, S. 38

S

Salzberger, B. p. 18
Scheiber, C. p. 33
Schindler, D. p. 29
Schleenvoigt, B. p. 43
Schlott, F. p. 33
Schmidt, D. p. 43
Schmidt, R. p. 29
Schneider, J. p. 15
Schneider, T. p. 8
Schneidewind, A. p. 15, p. 18
Schnettler, E. p. 32
Schober, K. p. 30
Scholten, M. p. 27
Schughart, K. p. 26
Schulze, M. p. 34
Schütz, M. p. 13
Schwarze, L. p. 26
Schwengers, O. p. 24
Seidel, D. p. 9
Seifert, H. p. 14
Seybold, U. p. 15, p. 18
Sierra, S. p. 24
Sinha, B. p. 14
Slavetinsky, C. p. 28
Slevogt, H. p. 34
Solbach, W. p. 12
Sommerer, C. p. 29
Song, Y. p. 40
Stecher, M. p. 25
Stellbrink, H. p. 12
Stottmeier, B. p. 42
Strauss, C. p. 40
Streeck, H. p. 12
Struck, N. p. 40
Struve, C. p. 27
Stubbe, H. p. 30
Suárez, I. p. 15

T

Tacconelli, E. p. 14, p. 16
Tergast, T. p. 41
Theobald, S. p. 31

Thye, T. p. 17
Toikkanen, S. p. 34
Tsakmaklis, A. p. 29

U

Ulrich, R. p. 43

V

Vehreschild, M. p. 13
Volz, A. p. 20, p. 31
von Hahn, T. p. 10

W


Walter, K. p. 39
Wanker, M. p. 41
Weissinger, E. p. 29
Wichers, J. p. 39
Wieler, L. p. 12, p. 16
Wienhold, S. p. 22
Wilde, B. p. 30
Willmann, M. p. 14
Witt, S. p. 37
Wittner, M. p. 42
Witzke, O. p. 11
Wunderlich, J. p. 39


X

Xanthopoulou, K. p. 14

Z

Zhang, L. p. 27
Ziegler, U. p. 10
Zipperer, A. p. 13





DZIF Prize for Translational Infection Research

The DZIF will award the fourth DZIF Prize for Translational Infection Research endowed with EUR 5.000,-.

The prize will be awarded during the DZIF Annual Meeting in Hamburg, 28 September 2017, 14:30 – 15:00, where the recipient will have a chance to present his or her research.

Travel Grants

On behalf of Meta-Alexander-Foundation the German Society of Infectious Diseases e.V. (DGI) is awarding **5 travel grants** in the amount of **EUR 500,-** each for the **participation in the Joint Annual Meeting of the DGI and DZIF**.

DZIF-Graduate Student Award of DGI 2017


The German Society of Infectious Diseases e.V. (DGI) together with the German Center for Infection Research e.V. (DZIF) will be awarding **3 prizes for PhD students**. The awards are endowed with **EUR 500,-** each.

The award ceremony will take place on Friday, 29 September 2017, 16:45 – 17:15 during the **Joint Annual Meeting of DGI and DZIF**.

Award for Clinical Infection Research 2017 of Meta-Alexander-Foundation

On behalf of the Meta-Alexander-Foundation the German Society of Infectious Diseases e.V. (DGI) has announced the Advancement Prize for Clinical Infection Research for the year 2017. The award is endowed with **EUR 5.000,-**.

The award ceremony will take place on Saturday, 30 September 2017, 11:30 – 11:50 during the **Joint Annual Meeting of DGI and DZIF**.



For a list of all exhibitors please see p.52.

Scientific Committee	German Society of Infectious Diseases e.V. (DGI) Nürnberger Straße 16 · 10789 Berlin www.dgi-net.de
	German Center for Infection Research e.V. (DZIF) Inhoffenstr. 7 · 38124 Braunschweig www.dzif.de
Venue	Hotel Empire Riverside Hamburg Bernhard-Nocht-Straße 97 · 20359 Hamburg
Workshop “Meet the Experts”	Thursday, 28 September 2017, from 18.30 „MS Hanseatic“, Landungsbrücken Take advantage of this opportunity to speak to and interact with high-ranking experts in various spheres of infectious diseases, and to ask questions you may have. At the check-in desk there will be lists to register yourself for the desired expert/topic. Registration for participation in the Meet the Experts Workshop is absolutely necessary, as the number of participants is limited. A cost contribution of EUR 50,- per person will be charged. Refreshments will be served.
Opening Hours Registration Desk	Thursday, 28 September 2017 08:00 – 18:00 Friday, 29 September 2017 07:30 – 17:30 Saturday, 30 September 2017 07:30 – 13:30
Organization	COCS GmbH · Congress Organisation C. Schäfer Rosenheimer Str. 145 c · 81671 Munich Phone: +49 (0)89/890677-0 Fax: +49 (0)89/890677-77 Email: felicitas.molnar@coocs.de
Certification	The Annual Meeting is certified by the Ärztekammer Hamburg with 27 CME points in category A. Furthermore the conference is certified by the Akademie für Infektionsmedizin e.V. with 20 iCME points. All participants will receive a confirmation of participation at the end of the conference at the congress office on site.

Registration	Please register until 11 September 2017 at www.dgi-dzif-kongress2017.de for the conference.	
Participation fee	Participant	EUR 140,-
	Doctoral student/student*	free entry
	Workshop “Meet the Experts”	EUR 50,- per person
	*) Please fax verification to +49 (0)89/890677-77. Without verification, the full price will be charged.	
	After your registration, you will receive automatically a confirmation and payment request. Please note that after 11 September 2017, payment can only be made at the venue.	
Payment	Please note „DGI/DZIF2017“ and the participant's name as intended purpose of the transfer: COCS GmbH HypoVereinsbank Munich IBAN DE30 7002 0270 0039 6131 40 BIC HYVEDE MMXXX Purpose: „DGI/DZIF2017“ and name of the participant Please note that we do not cover any bank charges.	
Cancellation	For written cancellation by 11 September 2017, a cancellation fee of 30,- EUR will be charged. After this closing date, no refund of the participation fee is possible.	
Contact	COCS GmbH · Congress Organisation C. Schäfer Rosenheimer Str. 145 c · 81671 Munich Phone: +49 (0)89/890677-23 Fax: +49 (0)89/890677-77 Email: eva.stricker@coocs.de	
Employer authorization for participation	For the purposes of the FSA codex we kindly ask for clinicians/scientists as employed to obtain an authorization from your employer to participate in the conference if necessary. The congress is supported by pharmaceutical/medical companies. The sponsors have no influence on the scientific programme. The special sponsor symposium is clearly marked.	

Exhibitors

Exhibitors	Booth No.
Basilea Pharmaceutica International Ltd., Basel/Switzerland* EUR 10.000,- Silversponsoring www.basilea.com	04
Correvio GmbH, Bielefeld* EUR 1.425,- Booth www.correvio.com	10
Hain Lifescience GmbH, Nehren www.hain-lifescience.de	11
Illumina GmbH* EUR 1.425,- Booth www.illumina.com	06
InfectoPharm Arzneimittel GmbH, Heppenheim www.infectopharm.com	08
Janssen-Cilag GmbH, Neuss* EUR 5.000,- Bronzesponsoring www.janssen.com/germany	01
MSD SHARP & DOHME GMBH, Haar* EUR 24.500,- Goldsponsoring / Symposium / Poster Awards www.msdd.de	05
Pfizer Pharma PFE GmbH, Berlin* EUR 1.425,- Booth www.pfizer.de	07
RIEMSER Pharma GmbH, Greifswald www.riemser.com	03
Seegene, Düsseldorf* EUR 1.425,- Booth www.seegene.com	02
Thermo Fisher Scientific, Henningsdorf* EUR 1.425,- Booth www.thermoscientific.com/brahms	09

*Subjected to the regulations of the FSA-code the financial support of the FSA-members is revealed here by request.

Status printdate (August 2017) – without engagement.

Sponsors

We thank our sponsors very much for their support:

Goldsponsoring

MSD SHARP & DOHME GMBH, Haar*
www.msdd.de



Silversponsoring

Basilea Pharmaceutica International Ltd., Basel/Switzerland*
www.basilea.com



Bronzesponsoring

Janssen-Cilag GmbH, Neuss*
www.janssen.com/germany



MSD SHARP & DOHME GMBH

About MSD:

MSD is part of Merck & Co., Inc., headquartered in Kenilworth, NJ, USA – a global health care leader. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. Furthermore, MSD is aiming to enhance global health care and to improve access to health care through far-reaching health care policies, programs, and partnerships. In Germany, MSD is located in Haar, near Munich.

For more information, please contact MSD at:
phone +49 800 673 673 673
fax: +49 800 673 673 329
email: Infocenter@msdd.de
internet: www.msdd.de



Travel**by car****Traveling on freeway A7**

Leave A7 at exit number 29 "HH-Othmarschen" (arriving from the south through the "Elb-tunnel", take the lane on the right side). Afterwards continue eastbound into Behringstraße. Drive for 1.3 km, then turn right into Hohenzollernring and after another 600 m turn left into Bernadottenstraße. Stay on that street for approximately 2.5 km until the street is named Reeperbahn after a major intersection. After 460 m turn right into Davidstraße and drive into Bernhard-Nocht-Straße after 280m. Your destination is directly on the left hand side.

Traveling on freeway A1

Driving on the freeway A1 bear left at bifurcation (signposting in direction HH-Centrum/HH-Veddel) towards the bridges over the river "Elbe" into the Veddel Brückenstraße. Turn left into Amsinckstraße and drive for a total of 4.1 km, passing through a tunnel and onto the Willy-Brandt-Straße. At Zeughausmarkt turn left and follow Neumayerstraße. At the end of this street turn right into Seewartenstraße and head straight forward into Bernhard-Nocht-Straße. We welcome you on the right hand side.

Traveling on freeway A24

Drive at A24 until the end of the street in direction HH-Jenfeld. Arriving at the roundabout, take the second exit at Sievekingallee. Follow the street for 2.1 km until the name changes into Bürgerweide. Take one of two lanes on the right side of the street and after 450 m turn right into Spaldingstraße. The street turns into Amsinckstraße, please use one of the two lanes on your left hand side through the tunnel. After 2.5 km turn left into Zeughausmarkt and drive straight forward into Neumayerstraße. Turn right into Seewartenstraße. After the intersection take the Bernhard-Nocht-Straße. Your destination is on the right in the direction of travel.

Traveling on freeway A24

You can use the in-house underground car park (EUR 20,- per day, parking cannot be reserved in advance). Further car parks can be found in the surrounding area.

by public transportation**From Central Station Hamburg**

Either take the train S1 in direction Wedel or the train S3 in direction Pinneberg and get off at station Landungsbrücken or station Reeperbahn.

From Airport Hamburg

Take train S1 in direction Wedel and exit at station Landungsbrücken or station Reeperbahn.

by railway/with Deutsche Bahn

COCS GmbH • Congress Organisation C. Schäfer offers you exclusive discounted tickets in cooperation with Deutsche Bahn for your travel to the joint DGI/DZIF meeting.

You can book your event ticket at a national fixed price from every Deutsche Bahn railway station (while stocks last).

Event ticket (one-way) for a specific train (while available):

- 2nd Class EUR 49,50
- 1st Class EUR 79,50

Event ticket (one-way) totally flexible (always available):

- 2nd Class EUR 69,50
- 1st Class EUR 99,50

Book your ticket online at www.cocs.de or under the service number +49 (0)1806 - 31 11 53 1 with the keyword „COCS“.


Location

WIR SIND INFIZIERT VON DER LEIDENSCHAFT MENSCHEN MIT INFEKTIONSKRANKHEITEN ZU HELFEN.



MSD Antiinfektiva

www.msd-antiinfektiva.de



MSD engagiert sich seit nahezu 80 Jahren umfassend auf dem Gebiet der Antiinfektiva. Die Entwicklung innovativer Produkte hat dabei höchste Priorität. 2016 wurden die Ergebnisse der Phase-III-Studie eines Impfstoffes gegen Ebola von MSD präsentiert. Bereits seit 1987 verfolgt das weltweit am längsten laufende Medikamentenspenden-Programm MECTIZAN von

MSD mit Erfolg die Ausrottung der Flussblindheit und der Elefantiasis in betroffenen Ländern wie z. B. Kolumbien, Ecuador und Mexiko. Trotz aller Erfolge sterben jährlich weltweit immer noch bis zu 15 Mio. Menschen an Infektionskrankheiten – verursacht durch Viren, Bakterien, Pilze und Parasiten. Ihnen zu helfen war und ist unser Antrieb.